This study will be conducted according to the protocol and in compliance with 
Good Clinical Practice, the ethical principles stated in the Declaration of Helsinki, 
and other applicable regulatory requirements.  
Study Title:  A Phase 1/2 Trial of X4P -001 as Single Agent and in 
Combination with Axitinib in Patients with Advanced Renal 
Cell Carcinoma  
Investigational Drug:  X4P-001 
IND #:  124194  
ClinicalTrials.gov I D: [STUDY_ID_REMOVED]  
Sponsor:  X4 Pharmaceuticals, Inc.  
[ADDRESS_15249], 4th Floor  
Cambridge, MA [ZIP_CODE]  
Protocol Number:  X4P-001-RCCA  
Protocol Version, Date:  7.0, 08 June 2018 
Replaces Version, Date:  6.0, 01 Feb 2017  
CONFIDENTIALITY NOTE:  
The information contained in this document is privileged and confidential. Any distribution, copying, or disclosure 
is strictly prohibited unless such disclosure is required by [CONTACT_15986]. Persons to whom the 
information is disclosed must know th at it is confidential and that it may not be further disclosed by [CONTACT_476]  

X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)  
2 INVESTIGATOR STATEMENT  
I understand that all documentation provided to me by X4 Pharmaceuticals, Inc. (X4), or its 
designated representative(s) concerning this study  that has not been published previously will be 
kept in the strictest confidence. This documentation includes the study protocol, investigator 
brochure, case report forms, and other scientific data.  
This study will not commence without the prior written approval of a properly constituted 
Institutional Review Board/Independent Ethics Committee (IRB/IEC). No changes will be made 
to the study protocol without the prior written approval of X4 and the IRB/IEC, except where 
necessary to eliminate an immediate h azard to the patient.  
Prior to study start, the investigator is required to sign a protocol signature [CONTACT_16066]/her agreement to conduct the study in accordance with all of the instructions and procedures 
found in this protocol and to give access  to all relevant data and records to X4 as required. If an 
inspection of the clinical site is requested by a regulatory authority, the investigator must inform 
X4 immediately that this request has been made.  
I have read, understood, and agree to abide by a ll the conditions and instructions contained in 
this protocol.  
Investigator Signature  [CONTACT_16067]  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)  
[ADDRESS_15250]  OF ABBREVIATIONS  ................................ ................................ ................................ .........  9 
PROTOCOL  SYNOPSIS ................................ ................................ ................................ ..............  13 
SCHEMATIC OF THE  STUDY DESIGN ................................ ................................ ...................  26 
1. KEY ROLES  ................................ ................................ ................................ .....................  27 
2. INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC
RATIONALE  ................................ ................................ ................................ ....................  [ADDRESS_15251] of X4P -001 in Prior  Clinical  Studies  .......................  35 
2.2.5. Nonclinical Toxicity Studies  of X4P-001 ................................ ............  35 
2.3. Clinical Experience with  Related Compounds  ................................ .....................  36 
2.4. Rationale  ................................ ................................ ................................ ...............  36 
3. OBJECTIVES AND PURPOSE  ................................ ................................ .......................  37 
3.1. Primary  Objective  ................................ ................................ ................................ . 37 
3.2. Secondary  Objectives  ................................ ................................ ............................  37 
3.3. Exploratory  Objective  ................................ ................................ ...........................  37 
4. STUDY DESIGN AND ENDPOINTS  ................................ ................................ .............  38 
4.1. Description of the  Study  Design  ................................ ................................ ...........  38 
4.1.1. Part A (Phase 1) : X4P-001 with Axitinib – Dose -escalation  Cohorts  .. 38 
4.1.2. Part B  (Phase 2) : An Expansion Cohort of the RP2D of X4P -001 in 
Combination  with Axitinib  ................................ ................................ .. 42 
4.1.3. Part C: X4P -001 as a Single  Agent  (Monotherapy)  .............................  42 
4.2. Rationale for the Study Design, Including the Choice of  Control  Groups  ...........  43 
X4 Pharmaceuticals, Inc.   
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
4  4.2.1. Rationale for the  Study  Design  ................................ ............................  43 
4.2.2. Rationale for the  Dose Regimen  ................................ ..........................  43 
4.3. Endpoints  ................................ ................................ ................................ ..............  44 
4.3.1. Safety  Endpoints  ................................ ................................ ..................  44 
4.3.2. Efficacy  Endpoints  ................................ ................................ ...............  44 
4.3.3. PK and  PD Endpoints ................................ ................................ ...........  45 
4.3.4. Exploratory  Endpoints  ................................ ................................ .........  45 
5. STUDY ENROLLMENT  AND  WITHDRAWAL  ................................ ..........................  45 
5.1. Inclusion  Criteria  ................................ ................................ ................................ .. 45 
5.2. Exclusion  Criteria  ................................ ................................ ................................ . 46 
5.3. Strategies for Recruitment  and Retention  ................................ .............................  48 
5.4. Participant Withdrawal  or Termination  ................................ ................................  48 
5.4.1. Reasons for Withdrawal  or Termination  ................................ ..............  48 
5.4.2. Handling of Participant Withdrawals or  Termination  ..........................  49 
5.5. Premature Termination or Suspension  of Study  ................................ ...................  49 
6. STUDY DRUG(S)  ................................ ................................ ................................ ............  50 
6.1. Study Drug(s) and  Control  Description  ................................ ................................  [ADDRESS_15252] Storage  and Stability  ................................ ...............................  50 
6.1.4. Preparation  ................................ ................................ ...........................  51 
6.1.5. Dosing and  Administration  ................................ ................................ .. 51 
6.1.6. Route  of Administration  ................................ ................................ ....... 52 
6.1.7. Dose Adjustments/Modifications/Delays  ................................ ............  52 
6.1.8. Duration  of Therapy  ................................ ................................ .............  54 
6.1.9. Treatment  Compliance  ................................ ................................ .........  55 
6.2. Study Drug  Accountability  Procedures  ................................ ................................ . 55 
7. STUDY PROCEDURES  AND  SCHEDULE  ................................ ................................ ... 56 
7.1. Study  Procedures/Evaluations  ................................ ................................ ...............  56 
7.1.1. Baseline and  Safety  Assessments ................................ .........................  56 
7.1.2. Pharmacokinetic  Assessments  ................................ .............................  58 
7.1.3. Pharmacodynamic  Assessments  ................................ ..........................  59 
7.1.4. Efficacy Assessments  ................................ ................................ ...........  60 
7.2. Laboratory  Procedures/Evaluations  ................................ ................................ ...... 63 
7.2.1. Clinical  Laboratory  Evaluations  ................................ ...........................  63 
7.2.2. Other Assays  or Procedures  ................................ ................................ . 64 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)  
[ADDRESS_15253] of the Study  ..........................  67 
7.5. Appropriateness  of Measurements  ................................ ................................ ........  68 
8. ADVERSE  EVENTS  ................................ ................................ ................................ ........  68 
8.1. Definitions ................................ ................................ ................................ .............  68 
8.1.1. Adverse Events  (AE)  ................................ ................................ ...........  68 
8.1.2. Serious Adverse Events  (SAE)  ................................ ............................  69 
8.1.3. Adverse Drug Reaction  ................................ ................................ ........  70 
8.1.4. Suspected, Unexpected Serious Adverse  Reaction (S[LOCATION_003]R)  .............  [ADDRESS_15254]  ................................ ................................ ..... 76 
8.4.4. Reporting of  Pregnancy  ................................ ................................ ........  76 
8.5. Study  Halting Rules  ................................ ................................ ..............................  77 
8.6. Safety  Oversight  ................................ ................................ ................................ .... 77 
8.6.1. Procedures for Monitoring Risks Associated  with X4P -001 ...............  77 
8.6.2. Additional Procedures for Monitoring  Patient  Safety  ..........................  78 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)  
6 8.6.3. Data Review Committee (DRC)  ................................ ..........................  [ADDRESS_15255] at  Participating Sites  ...............................  79 
9.2. Study  Monitoring Visits  ................................ ................................ ........................  80 
9.2.1. Site Qualification and  Initiation  Visits  ................................ .................  80 
9.2.2. Interim  Monitoring Visits  ................................ ................................ .... 80 
9.2.3. Study  Closeout  Visit  ................................ ................................ .................  81 
10. STATISTICAL  CONSIDERATIONS ................................ ................................ ..............  82 
10.1. Statistical and  Analytical  Plans  ................................ ................................ .............  82 
10.2. Statistical  Hypotheses  ................................ ................................ ...........................  82 
10.3. Analysis  Datasets  ................................ ................................ ................................ .. 82 
10.4. Description of  Statistical  Methods  ................................ ................................ ........  83 
10.4.1. General Approach  ................................ ................................ ................  83 
10.4.2. Baseline Descriptive Statistics  ................................ .............................  83 
10.4.3. Analysis of the  Safety  Analyses  ................................ ...........................  83 
10.4.4. Analysis of the  Efficacy  Endpoint(s)  ................................ ...................  84 
10.4.5. Planned Interim  Analyses  ................................ ................................ .... 84 
10.4.6. Multiple Comparison/Multiplicity  ................................ .......................  84 
10.4.7. Tabulation of Individual  Response Data  ................................ ..............  85 
10.4.8. Exploratory  Analyses  ................................ ................................ ...........  85 
10.4.9. Pharmacokinetic  Analyses  ................................ ................................ ... 85 
10.5. Sample Size  ................................ ................................ ................................ ...........  85 
10.6. Measures to Minimize Bias  ................................ ................................ ..................  86 
10.6.1. Enrollment/ Randomization/  Masking Procedures  ..............................  86 
10.6.2. Evaluation of Success  of Blinding  ................................ .......................  86 
10.6.3. Breaking the Study  Blind/Participant  Code  ................................ .........  86 
11. SOURCE DOCUMENTS AND ACCESS TO SOURCE  DATA/DOCUMENTS  ..........  87 
11.1. Medical  Records  ................................ ................................ ................................ ... 87 
11.2. Study -Specific Source Documents  ................................ ................................ ....... 87 
11.3. Source Documents  Requirements  ................................ ................................ .........  88 
11.4. Electronic Case Report  Forms  (eCRFs)  ................................ ................................  88 
12. QUALITY ASSURANCE AND  QUALITY CONTROL  ................................ ................  89 
12.1. Study  Monitoring  ................................ ................................ ................................ .. 89 
12.2. Case Report  Form  Completion  ................................ ................................ .............  89 
12.3. Computerized Systems / Medical Records  as Source Data  ................................ .. 89 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)  
7 12.4. Audits  and Inspections  ................................ ................................ ..........................  89 
12.5. Resolution  of Deficiencies  ................................ ................................ ....................  90 
13. ETHICS/PROTECTION OF  HUMAN SUBJECTS  ................................ ........................  [ADDRESS_15256]/Independent  Ethics  Committee  ................................ . 90 
13.3. Informed Consent  Process  ................................ ................................ ....................  91 
13.3.1. Consent/assent and Other Informational Documents Provided to 
Participants  ................................ ................................ ...........................  [ADDRESS_15257] OF TABLES IN THE TEXT  
Table 1 -1: Schedule of  Events  ................................ ................................ ................................ ... 23 
Table 1 -2: Estimated  Blood  Volumes  ................................ ................................ ........................  25 
Table 2 -1: Prior Clinical Studies Conducted using X4P -001 – Protocol Number,  Study  Title,  
and Publication1 ................................ ................................ ................................ ................................ ........................  31
Table 2 -2: Prior Clinical Studies Conducted using X4P -001 – Study  Population, Objectives,  31 
X4 Pharmaceuticals, Inc.   
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
8  Table 6 -1: Physical and Chemical Properties of Active Ing redient  (Drug  Substance)  ..............  50 
Table 6 -2: Formulation of  Drug Product  ................................ ................................ ...................  50 
Table 6 -3: Dose Modification Levels for  X4P-001 ................................ ................................ ... 53 
Table 7 -1: ECOG PS Definitions  ................................ ................................ ...............................  58 
Table 7 -2: Candidate Blood Biomarkers  ................................ ................................ ...................  59 
Table 7 -3: RECIST – Definitions of Response Categories for Target and  Non-Target  Lesions6 2 
Table 7 -4: RECIST – Overall Respo nses Based on Target Lesions, Nontarget Lesions,  and 
New Lesions  ................................ ................................ ................................ .............  62 
Table 7 -5: Safety  Laboratory  Tests  ................................ ................................ ............................  63 
Table 8 -1: Reporting the Date and Time of Onset of AE for Different Types  of Events  ..........  72 
Table 8 -2: Date and Time of Outcome for AE by [CONTACT_15987]  ................................ ............  74 
Table 8 -3: Monitoring Procedures for Risks Identified in Prior Studies  of X4P-001 
(AMD11070)  ................................ ................................ ................................ ............  77 
Table 10 -1: Relationship between Underlying DLT Rate and Probability of Dose Escalation ...85  
Table 18 -1:   Protocol  Revision  History  ................................ ................................ ........................  [ADDRESS_15258] OF FIGURES IN THE TEXT  
 
Figure 1 -1: Overview of  Study  Design  ................................ ................................ .......................  26 
Figure 4 -1: Study Design for  Part A  ................................ ................................ ...........................  39 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)  
[ADDRESS_15259]  Aspartate transaminase  
AUC  Area under the concentration -versus -time curve  
BID Twice daily  
ccRCC  clear cell Renal Cell Carcinoma  
CI Confidence interval  
Cmax Maximum concentration  
Cmin[12 hr] Minimum concentration at [ADDRESS_15260] Computed tomography  
CV Coefficient of variation  
CXCL12  C-X-C chemokine ligand type 12 (also designated SDF -1)
CXCR4  C-X-C chemokine receptor type 4
CYP  Cytochrome P450  
DBP  Diastolic blood pressure  
DLT  Dose -limiting toxicity  
DCR  Disease Control Rate  
DDI Drug -drug interaction  
DRC  Data  Review Committee  
EC Effective concentration  
X4 Pharmaceuticals, Inc.   
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
10  Abbreviation  Explanation  
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  Electronic case report form  
EDC  Electronic data capture  
Emax Maximum exposure  
EOS  End-of-study  
EOT  End-of-treatment  
FDA  Food and Drug Administration (U.S.)  
FGFR  Fibroblast growth factor receptor  
GCP  Good Clinical Practice  
GI Gastrointestinal  
GMP  Good Manufacturing Practice  
HBsAg  Hepatitis B surface antigen  
HCV  Hepatitis C virus  
HIF-α hypoxia -inducible factor1  
HIV Human immunodeficiency virus  
HR Heart rate  
ICH International Conference on Harmonization  
IEC Independent Ethics Committee  
IND Investigational New Drug Application  
IRB Institutional Review Board  
iRECIST  Modified RECIST 1.1 for  immune based  therapeutics  
ITT Intent -to-treat 
IUD Intrauterine device  
LFT Liver function tests  
MDSC  Myeloid -derived suppressor cell  
MedDRA  Medical Dictionary for Regulatory Activities  
MRI  Magnetic resonance imaging  
MS/MS  Tandem mass spectrometry  
MTD  Maximum tolerated dose  
X4 Pharmaceuticals, Inc.   
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
[ADDRESS_15261]  Response Evaluation Criteria in Solid Tumors  
RP-HPLC  Reversed -phase high performance liquid chromatography  
RP2D  Recommended phase 2 dose  
SAE  Serious adverse event  
SAP Statistical Analysis Plan  
SBP Systolic blood pressure  
SD Stable disease  
SDF-1α Stromal -derived -factor 1α (also designated CXCL12)  
SOD  Sum of diameters  
S[LOCATION_003]R  Suspected unexpected serious adverse reaction  
T1/2  Half-life 
T4 Thyroxin  
X4 Pharmaceuticals, Inc.   
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
[ADDRESS_15262]  Upper limit of normal  
US [LOCATION_002]  
VEGF  Vascular endothelial growth factor  
VEGFR  Vascular endothelial growth factor receptor  
 
Abbreviation  Explanation  
VHL  Von Hippel -Lindau syndrome  
VL Volume of distribution  
WBC  White blood cell  
WOCP  Women of childbearing potential  
β-hCG  Beta-human chorionic gonadotropin  
X4 Pharmaceuticals, Inc.   
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
13  PROTOCOL SYNOPSIS  
 
Study title  A Phase 1/[ADDRESS_15263], 4th Floor  
Cambridge, MA [ZIP_CODE]  
Phase  1 / 2 
Study centers / 
countries  Multiple study centers globally  
Planned study period  First patient enrolled: Q2 [ADDRESS_15264] patient enrolled: Q1 [ADDRESS_15265] visit: Q1 2019 (anticipated)  
Study objectives  The primary objective is:  
• To evaluate the safety and tolerability of escalating dose levels of 
X4P-001, both in combination with axitinib and as single agent, in 
patients with advanced clear cell Renal Cell Carcinoma  (ccRCC).  
Secondary objectives are:  
• To assess the treatment effect (clinical activity) of X4P-001, both in 
combination with axitinib and as single agent, in patients with 
advanced ccRCC using Response Evaluation Criteria in Solid 
Tumors (RECIST) v1.1 [ Eisenhauer 2009 ], including progression 
free survival  (PFS).  
• To characterize the pharmacokinetics (PK) of escalating dose levels 
of X4P-001 administered  orally.  
The exploratory objectives are:  
• To investigate associations between the treatment effect of X4P- 
001 (in combination with axitinib and as a single agent) and 
selected pharmacodynamic and disease -related biomarkers  (e.g.,  
 
X4 Pharmaceuticals, Inc.   
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
14   
 
 
 circulating CD34+ cells, plasma levels of soluble VEGF [vascular 
endothelial growth factor] receptor).  
• To assess the treatment effect (clinical activity) of X4P-001, both in 
combination with axitinib and as single agent, in patients with 
advanced ccRCC using modified Response Evaluation  Criteria in 
Solid Tumo rs for immune -based therapeutics (iRECIST) 
[Seymour  2017].  
Study design and plan This study will be conducted in patients with advanced ccRCC and will 
comprise 3 parts.  
• Part A  (Phase 1)  will assess the safety and tolerability of 
escalating dose levels of X4P -001 in combination with axitinib, a 
TKI approved  for use in this setting [Axitinib US prescribing 
information, 2014 ]. The X4P -001 dose level for the initial cohort is 
200 mg twice daily (BID). Subsequent cohorts will be administered 
X4P-001 once daily (QD). The initial QD dose level will be 400 
mg QD (representing the same total daily exposure as 200 mg 
BID), and then progressing to 600, 800, and 1200 mg. A safe 
maximum tolerated dose (MTD) and/or recommended phase 2 
dose (RP2D) will be identified in Part A. The RP2D may be the 
same as the MTD or may be lower (see Section  4.1.1 ). 
• Part B (Phase 2) is an expansion cohort assessing the safety, 
tolerability,  and treatment effect of the RP2D of X4P-001 in 
combination with axitinib in approximately 45 patients. If the 
RP2D is determined before reaching the MTD, Part B may be 
initiated while Part A is ongoing (see Section  4.1.2 ). 
• Part C will assess the safety, tolerability, and treatment effect of 
X4P-001 as monotherapy in patients with advanced ccRCC and 
may be initiated after the MTD of X4P-001 with axitinib is defined 
in Part A. If that MTD was ≤800 mg QD, then the MTD as 
monotherapy will be defined by [CONTACT_15988] - 
escalation cohort s to receive X4P -001 as a single agent up to, but 
not exceeding, 1200 mg QD (see Section  4.1.3 ). 
Planned number of 
patients  • Part A: Dose -escalation cohorts for X4P-001 in combination with 
axitinib; estimated to enroll approximately 15  patients.  
• Part B: Expansion cohort at the RP2D of X4P-001 in combination 
with axitinib; approximately 45 patients will be  enrolled.  
X4 Pharmaceuticals, Inc.   
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
15   
 
 
 • Part C: Dose -escalation (if needed after Part A) cohorts of X4P-001 
as single agent (monotherapy); Expansion cohort of approximately 
15 patients.  
Schedule of visits and 
assessments  The overall study schedule is as follows:  
• Screening will be done within 28 days prior to Day 1 (the first dose 
of study  drug).  
• Treatment is scheduled to be administered continuously; one  cycle 
is 28 days. Missed doses will be considered  skipped.  
• Assessments for treatment response (or disease progression) are 
scheduled for every 8 weeks (± 4 calendar days) starting from 
Cycle 1 Day 1 for 80 weeks (20 cycles) and then every 12 weeks 
thereafter.  
• The End -of-Treatment (EOT) visit will be performed with in [ADDRESS_15266] dose of study drug or the decision to terminate 
treatment  prematurely.  
• End-of-Study (EOS) visit, the final study event, will be performed 
30 days (± 4 calendar days) after the last dose of study drug. In the 
event the EOT visit is delayed, the EOS visit will be performed at 
least 14 days after the EOT  visit.  
Safety Assessments:  
Safety assessments include ongoing monitoring for clinical adverse events 
(AEs); and regularly scheduled measurement of vital signs; physical 
examinations; o phthalmologic examinations; laboratory tests (hematology  
and clinical chemistry); thyroid function tests (free thyroxin and thyroid 
stimulating hormone) (Parts A and B only); and electrocardiograms 
(ECG). Additional unscheduled assessments may be conducted  at 
Investigator’s discretion.  
Efficacy Assessments:  
Tumor Response assessments will be conducted every 8 weeks for 80 
weeks (20 cycles) and then every [ADDRESS_15267] v1.1 criteria [ Eisenhauer 2009 ]. Treatment decisions will be 
made by [CONTACT_15989]. For data analysis, scans will be 
reviewed and interpreted by a blinded central review committee comprising  
X4 Pharmaceuticals, Inc.   
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
16   
 
 
 up to 3 experienced radiologists.  
Tumor Response assessments may be explored by [CONTACT_15990] -based 
therapeutics (iRECIST) [ Seymour 2017 ]. Patients  enrolled with a 
history or current evidence of central nervous  system (CNS) disease 
should have brain imaging by [CONTACT_9252] (MRI) at 
baseline and, thereafter, as clinically indicated.  
Pharmacokinetics  
PK samples will be obtained on all patients in Part A and Part C, and at 
least 15 patients in Part B as follows:  
• Cycle 1 Day 1: pre -dose ( -30 min); post -dose at 30, 60, 90 min 
(each ±5 min) and 2, 3, 4 hr (each ±15 min) 
• Cycle 1 Day 15: pre -dose ( -10 min); post -dose at 30, 60, 90 min 
(each ±5 min) and 2, 3, 4, 8 hr (each ±15 min) 
• Cycle 2 Day 1 and Day 15: pre-dose ( -10 min) 
In Part B, for patients who will not collect extensive PK samples on Cycle 1 
Day 1 and Day 15, pre -dose ( -10 min) samples will be collected on Cycle 1 
Day 1, Cycle 1 Day 15, Cycle 2 Day 1, and Cycle 2 Day 15.  
All PK samples will be used to analyze X4P -001. PK samples collected in 
Part B may be used to analyze axitinib as well.  
These visits will be scheduled for early in the day and patients will be 
instructed to arrive at the clinic fasting and having not taken their morning 
dose of study  drug(s).  
Pharmacodynamics  
Whole blood samples will be obtained concurrently with scheduled PK 
samples on Cycle 1 Day 1 and Cycle 1 Day 15 only (see above) for total 
white blood cell (WBC) counts and counts of circulating CD34+ positive 
cells.  
If sample yields permit, additional investigational immunomodulatory 
subsets may be analyzed. Pharmacodynamic samples will not be drawn at 
Cycle 2 Day 1 and Cycle 2 Day 15.  
Biomarkers  
Blood samples for biomarker assessment [serum and peripheral blood 
mononuclear cel ls (PBMC)] will be collected as scheduled for potential 
treatment - and tumor -related biomarkers that reflect the pharmacologic 
X4 Pharmaceuticals, Inc.   
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
[ADDRESS_15268] meet all of the following criteria to be eligible for study  
participation:  
1. Be at least [ADDRESS_15269] one prior course of treatment for ccRCC (see  
Section 5.2. for specific  exclusions).  
5. Have on computed tomography (CT) imaging done within [ADDRESS_15270] v1.1 [ Eisenhauer 2009 ]. 
6. Agree to use contraception as  follows:  
• For women of childbearing potential (WOCP, see Section  
[IP_ADDRESS]  for definition), agree to use highly effective 
contraceptive methods from screening, through the study, and 
for at least [ADDRESS_15271] dose of study drug.  
• For males, agree to use a condom with any WOCP sexual 
partner from Day [ADDRESS_15272] dose of study  drug.  
7. For women of childbearing potential (WOCP), h ave a negative 
pregnancy test (serum or urine) on Day 1 prior to initiating study 
treatment.  
8. Be willing and able to comply with this protocol.  
Exclusion criteria  Patients with any of the following will be excluded from participation in the 
study:  
1. Has life expectancy of less than 3  months.  
2. Has performance status Grade >2 (Eastern Cooperative 
Oncology Group [ECOG]  criteria).  
3. Has [LOCATION_001] Heart Association Class III or IV heart failure or 
uncontrolled hypertension (systolic blood pressure [SBP] ≥160  mm 
Hg; diastolic blood pressure [DBP] ≥100 mm  Hg). 
4. Has previously received  X4P-001. 
5. Parts A and B only : Has received a prior course of axitinib.  
Parts A and B only : Has received mechanistic target of  rapamycin 
X4 Pharmaceuticals, Inc.   
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
18  (mTOR) inhibitor(s) as their only prior treatment for ccRCC.  
7. Has a prior history or current evidence of intracranial (CNS) 
metastatic RCC, except for ≤3 lesions treated by [CONTACT_15991] 
(or any type of radiation) or excisional surgery, clinically 
stable for at least 4 weeks, and without evidence of recurrence 
on MRI imaging at  screening.  
8. Has ongoing acute clinical AEs of National Cancer Institute (NCI) 
Common Terminology Criteria for Adverse Events (CTCAE) 
Grade >1 resulting from prior cancer therapi[INVESTIGATOR_014] (except alopecia, 
TKI-related hand -foot syndrom e, or thyroid  dysfunction).  
9. Has had within the past 6 months the occurrence or persistence of 
one or more of the following medical conditions that could not be 
controlled with usual medical care (e.g., required emergency care 
or hospi[INVESTIGATOR_059]): hypertens ion, angina, congestive heart failure, 
diabetes, seizure  disorder.  
10. Has had within the past 6 months the occurrence of one or more of 
the following events: myocardial infarction, cerebrovascular 
accident, deep vein thrombosis, pulmonary embolism, hemorrhage 
(CTCAE Grade 3 or 4), chronic liver disease (meeting criteria for 
Child -Pugh Class B or C), a second active malignancy (excluding 
malignancies that were treated curatively and have not recurred 
within 2 years  prior to study treatment; completely resected basal 
cell and squamous cell skin cancers; any malignancy considered 
to be indolent and that has never required therapy; and completely 
resected carcinoma in situ of any type ), organ transplantation.  
11. Has had w ithin the [ADDRESS_15273] during the study period, surgery requiring  general 
anesthesia.  
12. Has a known history of a positive serology or viral load for HIV or 
a known history of AIDS.  
13. Has, at screening, serologic laboratory tests meeting one or more of 
the following  criteria:  
• An indeterminate or positive test for antibody to hepatitis C 
virus (HCV), unless documented to have no detectable viral 
load on 2 independent  samples.  
• A positive test for hepatitis B surface antigen  (HBsAg).  
14. Has, at screening, safety laboratory tests meeting one or more of  the 
following  criteria:  
• Hemoglobin <8.0 g/dL 
X4 Pharmaceuticals, Inc.   
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
19  • Absolute neutrophil count (ANC) <1,500/μL  
• Platelets <75,000/μL  
• Creatinine >2.0x ULN  
• Serum aspartate  transaminase (AST) >2.5x upper limit of 
normal (ULN)  
• Serum alanine transaminase (ALT) >2.5x ULN  
• AST and ALT >5x ULN for patients with liver metastasis  
• Total bilirubin >1.5x ULN (unless due to Gilbert’s Syndrome, 
total bilirubin > 3.0x ULN and direct bilir ubin > 1.5x ULN)  
15. Has received other anti -cancer therapy within the following specified 
intervals prior to Day 1:  
• TKI within 2 weeks.  
• Radiation therapy within 2 weeks.  
• Bevacizumab within 4 weeks.  
• Other chemotherapy (e.g., mitomycin -C, nitrosourea) or 
immuno therapy (e.g., antibody, cytokine) within 4 weeks.  
• For investigational anti -cancer therapi[INVESTIGATOR_014], the interval will be 
determined in consultation with the Medical Monitor.  
16. Has, within 2 weeks prior to Day 1, received a medication prohibited 
based on CYP3A4 int eraction (see Section [IP_ADDRESS] for details).  
17. Has, within 2 weeks prior to Day 1, received systemic 
corticosteroids exceeding prednisone 10 mg per day or equivalent; 
for other immunosuppressive agents, the exclusionary dose and 
duration will be determined in  consultation with the Medical 
Monitor.  
18. Is nursing.  
19. Has, at the planned initiation of study drug, an uncontrolled 
infection.  
20. Has any other medical or personal condition that, in the opi[INVESTIGATOR_15960], may potentially compromise the safety or 
compliance of the patient, or may preclude the patient’s successful  
Investigational 
Medicinal Product: 
dose/mode of 
administration/dosing 
schedule  The investigational agent is X4P -001. X4P -[ADDRESS_15274] ered orally, at a consistent time each 
morning (±2 hours) with no food or drink (except water) for at least [ADDRESS_15275] -dose.  
• For first cohort in Part A, taken as 2 capsules (representing 200 mg) 
twice daily. The mor ning dose should be taken at a consistent time 
X4 Pharmaceuticals, Inc.   
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
20  (±2 hr). The second daily dose should be taken 12 hr later (±3 hr). 
• For subsequent cohorts in Part A and for Parts B and C, taken as 4 
to 12 capsules (representing 400 - 1200 mg) once daily in the 
morning at a  consistent time (±2  hr). 
Manufacturing of a 200 mg capsule formulation is under development and 
may be introduced into the clinic when released.  
All patients enrolled in Parts A and B also will receive treatment with 
axitinib at 5 mg orally BID in additio n to X4P -001 at the assigned dose level. 
Axitinib will be supplied as 5 mg tablets, with one tablet administered orally 
BID (continuous dosing).  
Reference therapy: 
dose/mode of 
administration/dosing 
schedule  None.  
Planned treatment 
duration per patient  Patients who do not experience a DLT in Cycle 1 (Parts A and C) and 
patients in Part B will remain on study treatment until they experience 
progression of disease, unacceptable toxicity, or other specified reason for 
discontinuation ( Section 5.4.1 ). In Part A and Part C, patients who 
experience a DLT during Cycle 1 will be withdrawn from the study and will 
not receive further study treatment.  
Safety and Efficacy 
Endpoints:  Safety endpoints are:  
• AEs 
• Clinical observations (e.g., vital signs, physical  examination)  
• Laboratory tests, (e.g., clinical chemistry, hematology,  and thyroid 
function tests [Part A and Part B  only])  
• ECGs  
• Ophthalmologic  examination  
Treatment effect (tumor response) will be analyzed using RECIST v1.1 
[Eisenhauer 2009 ] to determine the following efficacy endpoints:  
• Objective response rate (ORR) (Complete Response [CR] + Partial 
Response  [PR])  
• Time to objective  response  
• Duration of objective  response  
• Disease control rate (CR + PR + Stable  Disease)  
• Time to progression  
• PFS 
• Treatment effect (tumor response) and efficacy endpoints may be 
explored using the iRECIST assessment [Seymour 2017].  
X4 Pharmaceuticals, Inc.   
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
21  Statistical methods 
(includes sample size 
calculation)  Sample Size:  
The maximum  numbers of  patients planned to be enrolled in Parts A and C 
are as follows:  
• Part A, Dose -escalation: up to 30 patients in total (up to 6 patients 
per dose level; 5 planned dose  levels)  
• Part B, RP2D expansion cohort: approximately 45 patients will  be 
enrolled;  
• Part C, Dose -escalation: up to 18 patients in total (up to 6  
patients per single agent dose -escalation level; maximum 3 dose  
levels);  
• Part C, Single agent Expansion: maximum 15  patients  
Dose -escalation in Part A (and, if needed, in Part C) employs the standard 
3+3 design.  
In Part B, approximately 45 patients will be enrolled and dosed with X4P - 
001 in the combination of axitinib to provide a preliminary assessment of 
both safety and anti -tumor activity. With 45 subjects at the RP2D, the two - 
sided 90% confidence  interval width for any binary response rate (e.g., DLT 
or binary PD markers) will be approximately 0.24, assuming a 40% response 
rate. If a dose de -escalation occurs after the first 12 patients, the remaining 
33 patients will be dosed at a lower dose leve l. With 33 patients, the 
confidence interval width will be approximately 0.28 for a binary response 
rate. 
Part C has an expansion cohort at or below the MTD to further assess the 
toxicity at that dose level. With 15 patients, there is a 79% chance of 
obser ving at least one AE with the true underlying rate of 10%, and a 54% 
chance of observing at least one AE with true underlying rate of 5%.  
 Statistical Methods:  
The primary objective of the study is safety and tolerability. AEs will be 
coded using Medical Dictionary for Regulatory Activities (MedDRA) 
version 16.0 (or later) and tabulated by [CONTACT_15992], grade, and relationship to 
study therapy. Laboratory results, vital signs, and ECG parameters will be 
summarized using descriptive statistics. Laboratory values w ill also be 
graded according to NCI CTCAE, Version 4.03, and summarized in shift 
tables. Dose -limiting toxicity (DLT) events will be summarized by [CONTACT_15993] A and identified in the listings.  
Safety observations will be analyzed using descriptive statistics and  
tabulation. No formal statistical comparisons are planned. All safety data 
will be presented in listings.  
Analysis of Tumor Response, ORR and Disease Control Rate (DCR) will 
be tabulated using best overall response, by [CONTACT_15994], incorporat ing 95% 
exact Clopper -Pearson confidence intervals (CI)  for ORR and disease 
control rate . The analysis will be based on inte nt-to-treat (ITT) and 
Clinically Evaluable patient populations.  
X4 Pharmaceuticals, Inc.   
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
22  Median time to objective response, TTP, PFS as well as the proportio n of 
patients with PFS at 6 and 12 months (with 95% CI) will also be derived 
from Kaplan -Meier estimates.  
Duration of ORR  will be summarized as median (with 95% CI) and 
interquartile range estimated using Kaplan - Meier method with 
corresponding 95% CIs.  
Tumor Response and endpoints listed above may also be explored by [CONTACT_15995] -based therapeutics  (iRECIST ) [Seymour 2017 ]  
Schedules of events:  The schedule of events an d estimated blood volume collections are 
presented in Table [ADDRESS_15276] -dose intervals are relative to the time of oral administration of 
X4P-001, designated 0 hr.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
23 
  
Table  1-1: Schedule of  Events  
 
 
 
Procedure1  
 
 
Screening 
Visit2  
 
 
Cycle 1   
 
 
Cycle 2   
 
 
Cycle 3   
 
 
Cycle 4  Subsequent 
Odd - 
Numbered 
Cycles 5 -19 Subsequent 
Even - 
Numbered 
Cycles 6 -20 Repeats every 12 weeks4  
 
 
EOT5  
 
 
EOS6 Cycle 
21 Cycle 
22 Cycle 
23 
D13 D15 D1 D15 D1 D15 D1 D15 D1 D1 D1 D1 D1 
Informed Consent  X                
Inclusion/Exclusion Criteria  X                
Medical History  X                
History of Renal Cell 
Carcinoma  X                
Vital Signs7 X X X X X X  X  X X X   X X 
Body weight & height8 X X  X  X    X  X   X X 
ECOG PS  X     X    X  X   X  
Physical Examination  X X  X  X    X  X   X X 
Ophthalmologic Examination9 X10   X  X  X  X  X   X  
12-Lead ECG  X X X11   X    X  X   X X 
Safety Laboratory Tests12, [ADDRESS_15277] Imaging21 X     X    X  X   X22  
Administration of Study 
Drug(s) in clinic23  X X X X            
Dispense eye drops and nasal 
spray24  X               
AE & Concomitant Med 
Monitoring25 X X X X X X X X X X X X X26 X26 X X 
 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
[ADDRESS_15278] administration of study drug is designated Day 1. Each 
Cycle represents 4 weeks (28 days). Pre - and post -dose intervals are relative to the time of oral administration, designated 0  hr. 
2. Screening activities may be initiated up to 28 days prior to Day  1. 
3. To allow for holidays and scheduling flexibility, on-treatment visits may be performed within ± 3 calendar days of the day indicated; ophthalmology exams and CT imaging 
within ± 4 calendar  days.  
4. For cycles >23, perform assessments as indicated for Cycle 21-[ADDRESS_15279] dose of study drug or the decision to terminate treatment prematurely.  
6. The EOS visi t is scheduled for 30 days (± 4 days) after the last dose of study drug. In the event the EOT visit is delayed, the EOS visit will be performed at least 14 days after 
the EOT  visit.  
7. Vital signs comprise heart rate, blood pressure, and temperature. For patients dosed in clinic on PK collection days, vital signs will be performed  pre-dose.  
8. Body height needs to be measured at screening  only.  
9. Ophthalmologic exam – see Section [IP_ADDRESS] . for details . Note: an optometrist may complete the exam if all requirements can be met, including use of appropriate equipment to 
obtain the retinal photographs.  
10. Screening ophthalmologic exam reports and retinal photos must be submitted to the sponsor at least 5 busi ness days prior to Cycle 1 Day 1 to allow central review for 
eligibility  
11. ECG should be performed at 2 hr (± 15 mins)  post-dose 
12. Safety laboratory tests – hematology  and chemistry (see Section 7.2.1 for details).  
13. Safety laboratory tests should be drawn and sent to central laboratory for analysis.  
14. All laboratory tests required for screening will be performed by [CONTACT_2237]. Specimens should be submitted no more than 14 days prior to Day  1. 
15. Women of child -bearing potential only (see Section [IP_ADDRESS] ). On Day 1, a urine or serum pregnancy test will be done at the site and the results obtained prior to  dosing.  
16. Thyroid Function Tests are performed for Parts A and B only; Section 7.2.1 for details.  
17. Blood samples for tumor -related biomarkers; see Section [IP_ADDRESS] for details.  
18. PK and PD samples will be collected for all patients in Part A and Part C, and for at least 15 patients in Part  B. 
19. PK and PD samp les to be taken from 0-4 hr on Cycle 1 Day 1 and from 0-8 hr on Cycle 1 Day 15. See Section 7.1.2 and Section [IP_ADDRESS] for details of times for PK and PD  
dense sampling. For Part B subjects who do not complete PK/PD dense sampling (e.g. after the minimum 15 patients ’ samples are collected), a pre -dose PK sample will 
be collected at these visits . 
20. PK sample is collected at Pre-dose only.  
21. CT imaging of chest, abdomen, and pelvis; see Section [IP_ADDRESS] for details. Patients with history or current evidence of CNS disease should also have brain imaging by  [CONTACT_9268].  
22. CT imaging is not required at the EOT visit if performed within the previous 4 weeks and patient is being term inated for disease  progression.  
23. Study drugs will be self -administered by [CONTACT_15996], except at PK visits, when study drugs will be administered in the  clinic.  
24. See Section [IP_ADDRESS] for details.  
25. Concomitant illnesses tha t worsen or illnesses with onset in screening period will be recorded as AEs (see Section  8). 
26. Can be completed via telephone.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
25   
 
 
Table  1-2: Estimated Blood  Volumes  
 
 
 
Tests  MAX 
Vol 
(mL)  
per 
sample (s)  
 
Screening2 
Visit   
Cycle [ADDRESS_15280] 6,7  X            X X 
Serology7 2.5 X              
Total mL blood draw1
 9.5 86 82.5 24 10.5 18 5 18 5 18 5 18 18 18 
1. The volumes shown are estimates; final volumes may vary, but will not be more than 15% greater than shown.  
2. The schedule is presented relative to Study Cycle, Day within Cycle, and Time of Dosing. The calendar day of the first administration of study drug is designated Day 1. 
Each Cycle represents 4 weeks (28 days). Pre- and post -dose intervals are relative to the time of oral administration, designated 0  hr. 
3. PK and PD samples taken at 7 different time points. See Section 7.1.2 and Section 7.1.3 for sampling  times.  
4. PK and PD samples taken at 8 different time points. See Section 7.1.2 and Section 7.1.3 for sampling  times.  
5. PK samples taken at  pre-dose.  
6. Pregnancy testing will be done on WOCP  only.  
7. Done at the central lab; extra blood volume is not  required.  
8. The samples are taken on Cycle 21, 24, 27, etc. (every 3 cycles) until EOT.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
26 
  
 
SCHEMATIC OF THE STUDY DESIGN  
 
Figure 1 -1 presents an overview of the design of Parts A, B, and C of the study.  
 
Figure 1 -1: Overview of Study  Design  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part A  
X4P-001 with axitinib  
Part B  
X4P-001 with axitinib  
Dose Escalation Cohort  
 RP2D Dose -Expansion Study  
X4P-001 planned dose levels: 
200 mg BID;  
400, 600, 800, 1200 mg QD,  
in combination with axitinib  
Approximately  45 patients 
to receive: X4P -001 at 
RP2D in  
combination with axitinib  
Part C  
X4P-001 monotherapy  
 
Dose Escalation and  
Expansion Cohort  
 
If MTD with axitinib (Part A) 
is ≤800 mg QD, then 
additional monotherapy dose 
escalation cohorts may be 
enrolled to define the MTD of 
X4P-001 as single agent.  
 
Expansion Cohort:  
X4P-001 at or below MTD*  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
27   
 
1. KEY  ROLES  
 
 
Study Sponsor:  X4 Pharmaceuticals, Inc.  
[ADDRESS_15281]:   
  
X4 Pharmaceuticals, Inc.  
Telephone:   
E-mail:   
Sponsor Signatory:   
 
 X4 Pharmaceuticals,  Inc. 
E-mail:  
 
 
 
  
X4 Pharmaceuticals,  Inc. 
E-mail:   
 

X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
28   
 
2. INTRODUCTION: BACKGROUND INFORMATION  AND 
SCIENTIFIC  RATIONALE  
2.1. Background  Information  
In ~75% of patients with sporadic clear -cell renal cell carcinoma (ccRCC) there is functional loss 
of the VHL gene, typi[INVESTIGATOR_15961], but also silencing by [CONTACT_15997]. VHL encodes the 
von Hippel -Lindau tumor suppression protein which mediates proteolytic degradation of the 
hypoxia -inducible factor (HIF) -α [Turner 2002 ]. Loss of this function results in increased levels 
of HIF -α, increased expression of vascular endot helial growth factor (VEGF), tumor 
angiogenesis, and, ultimately, the hypervascularity characteristic of these malignancies. Multiple 
agents that block the activation of the VEGF pathway have been shown to improve outcomes, 
including:  
• Tyrosine kinase inhib itors (TKIs), such as sunitinib, axitinib, sorafenib or pazopanib, that 
block the VEGF signaling  pathway.  
• Bevacizumab, a monoclonal antibody, that binds circulating VEGF and thus prevents  the 
ligand from binding to the VEGF  receptor.  
Despi[INVESTIGATOR_15962], the approach is not 
curative. Although many patients respond initially, most of them experience relapse and 
progression. There is clear unmet need for agents that improve outcomes by [CONTACT_15998].  
CXCR4 (C -X-C chemokine receptor type 4) is the receptor for CXCL12 (C -X-C chemokine 
ligand type 12; also referred to as SDF -1α, stromal -derived -factor 1α). CXCL12 has potent 
chemotactic activity for lymphocytes and MDSCs (mye loid-derived suppressor cells), and is 
important in homing of hematopoietic stem cells to the bone marrow. CXCR4 is also expressed 
and active on multiple types of human cancers, including ccRCC, ovarian cancer, and melanoma, 
and increased expression of CXC R4 on tumor cells has been associated with significantly 
decreased overall patient survival [ Staller 2003 ; Sekiya 2012 ; Ejtesja, 2008 ; Maréchal 2009 ]. 
Multiple observations implicate the CXCL12/CXCR4 axis in contributing to the lack (or loss) of 
tumor responsiveness to angiogenesis inhibitors (also referred to as “angiogenic escape”). In 
animal cancer models interference with CXCR4  function has been demonstrated to disrupt the 
tumor microenvironment (TME) and unmask the tumor to immune attack by [CONTACT_15999], including  
• Eliminating tumor re -vascularization [ Righi 2011 ; Kioi 2010 ]. 
• Decreasing the infiltration of  MDSCs.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
29  • Increasing the ratio of CD8+ T cells to T regulatory (Treg) cells [ Righi 2011 ; Feig 2013; 
Fearon  2014 ]. 
These effects result in significantly decreased tumor burden and increased overall survival in 
xenograft, syngeneic, as well as transgenic, cancer models [ Righi 2011 ; Feig 201 3; Kioi 2010 ]. 
X4P-[ADDRESS_15282] [ Stone 2007 ], that has demonstrated 
activity in solid and liquid tumor models [Parameswaran 2011 ], and u npublished data] and has 
previously (under the designations AMD070 and AMD11070) been in Phase 1 and 2a studies 
involving a total of 71 healthy volunteers [ Stone 2007 ; Cao 2008 ; Nyunt 2008 ] and human 
immunodeficiency virus (HIV) -infected patients [ Moyle 2009 ; Study ACTG (DIAIDS) Protocol  
A5210 ]. These studies demonstra ted the following:  
• Oral administration of up to 400 mg twice daily (BID) for 3.5 days (healthy volunteers) 
and 200 mg BID for 8 -10 days (healthy volunteers and HIV patients) was generally safe 
and well -tolerated with no serious or severe treatment -related adverse events and no 
pattern of clinically significant laboratory  changes.  
• Pharmacodynamic activity, with dose - and concentration -related changes in circulating 
white blood cells (WBCs).  
• High volume of distribution (V L) suggesting high tissue  penetrance.  
We postulate that effective CXCR4 antagonism by X4P -001 would be of potential benefit in 
patients with advanced ccRCC and other cancers by [CONTACT_16000]:  
• Decreased recruitment of MDSC, resulting in increased anti -tumor immune  attack.  
• Sustained decrease in neoangiogenesis and tumor vascular  supply.  
• Interference with the autocrine effect of increased expression by [CONTACT_16001]4 
and CXCL12, its only ligand, thereby, potentially reducing cancer cell  metastasis.  
This clinical study in patients with advanced ccRCC will evaluate X4P -001 both as a single 
agent (monotherapy) and also in combination with axitinib, a small molecule TKI approved for 
second -line treatment of patients with ccRCC. We hypothesize that the comb ination has the 
potential to further improve outcomes by [CONTACT_16002][INVESTIGATOR_15963].  
2.2. Overview of  X4P-001 
X4P-001 was previously under development for the treatment of HIV infection based on the role 
of CXCR4 in vi ral entry into the cell. That program, which is presented in detail in the 
Investigator Brochure, included nonclinical toxicology studies and clinical studies using the free  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
[ADDRESS_15283] used was capsules containing 100 mg of the free base. 
The same formulation will be used in this protocol (see Section 6.1.2 ). 
During the earlier clinical studies, a p-hydroxybenzoate (PHB) salt form of the drug (designated 
AMD11070PHB) was identified for future manufacturing and development purposes. Animal 
toxicology studies (13 - and 26 -week duration) conducted with AMD11070PHB demonstrated 
unexpected findings, including retinal changes in albino rats treated for 26 weeks and notable 
gastrointestinal (GI) intolerance and liver changes in Beagle dogs treated for 13 weeks (see 
Investigator’s Bro chure).  
Although AMD11070PHB was never administered to humans and is not proposed for use in any 
clinical studies in this program, these observations were carefully considered in the safety 
monitoring plans for clinical studies of X4P ‑001. 
2.2.1. Prior Clinical S tudies Conducted Using  X4P-001 
The 4 clinical studies conducted under the prior development program included Phase 1 and 2a 
studies involved a total of 55 healthy volunteers [ Cao 2008; Nyunt 2008]  and 16 HIV -infected 
patients [ Moyle 2009 ; ACTG (DIAIDS) Protocol A5210 ]. Table 2 -1 shows the protocol 
numbers , titles, and related publications; Table 2 -2 summarizes the study populations,  objectives, 
numbers, dose administered, and  duration.  
These studies demonstrated the following:  
• Oral (PO) administration of up to 400 mg BID for 3.5 days (healthy volunteers) and 200 
mg BID for 8 -10 days (healthy volunteers and HIV patients) was generally safe and well - 
tolerated with no pattern of adverse events (AEs) or clinically significant laboratory 
changes.  
• T1/2 of X4P -001 is ~23 hours, supporting the use of QD dosing (see Investigator’s 
Brochure).  
• Pharmacodynamic activity, as assessed by [CONTACT_16003], was related to 
dose and duration of  treatment.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
31   
 
Table 2 -1: Prior Clinical Studies Conducted using X4P-001 – Protocol  Number,  Study 
Title, and  Publication1 
Protocol No.  Study Title  Publications  
A5191  A Phase I, Dose -Rising Study of AMD11070 In HIV -Seronegative Men To 
Assess the Safety and Pharmacokinetics After Single or Multiple Doses  Stone 2007  
AMD -1001  Multicenter, dose -finding safety and activity study of AMD11070 in HIV - 
infected patients carrying X4 -tropic virus  Moyle 2009  
AMD -1002  A Study of the Pharmacokinetic Interaction between AMD11070 and Substrates 
of CYP 3A4 and 2D6 Enzymes in Healthy Volunteers  Nyunt 2008  
A5210  Phase IB/IIA Dose -Finding Safety and Activity Study of AMD11070 (An Orally 
Administered CXCR4 Entry Inhibitor) in  HIV-Infected Patients  (unpublished)  
1 All studies were conducted between 3 Sep 2003 and 13 Jul  2006.  
 
Table 2 -2: Prior Clinical Studies Conducted using X4P -001 – Study  Population, 
Objectives, and  Exposures  
 
 
Study ID   
Study 
Population   
Study 
Objective  Cohort 
(A5191  
only)   
 
N  
Gender 
M/F2  
Dose & Regimen 
(All oral)   
 
Duration  
A51911 Healthy 
Volunteers  Dose escalation: 
Safety, PK  A-D 121 43 M, 0 Fa Single Dose 
50 to 400 mg  1 day  
   F, G, I  181  100 to 400 mg, BID  3.5 days (7 doses)  
  Effect of food, 
DDI of ritonavir  H, J, K  321  ≤3 doses, 200 mg or 
400 mg each  ≤3 doses over 6 to 
17 days  
A5210  HIV-infected  Safety  
Viral load 
reduction   6 3 M, 3 F  200 mg, BID  10 days  
AMD -1001  HIV-infected  Safety  
Viral load 
reduction   10 9 M, 1 F  100 mg, BID (N=2)  
200 mg, BID (N=8)  10 days  
AMD -1002  Healthy 
Volunteers  Safety  
Drug -drug 
interaction   12 9 M, 3 F  200 mg, BID  8 days  
1. Study A5191 enrolled 10 cohorts totaling 68 subjects representing 43 unique individuals. There were 3 subjects in each of 
the 4 single dose escalation cohorts (A-D) and 6 subjects in each of the 3 multiple dose escalation cohorts (F, G, I). No 
subject was enrolled in more than one of the dose escalation  cohort.  
2. Within each study the median age was ~40 years; overall age range  was 19 to 58  years.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
32   
 
2.2.2. Clinical Pharmacology of  X4P-001 
[IP_ADDRESS].  Clinical  Pharmacokinetics  
In the 4 previous clinical studies conducted by [CONTACT_16004] (Studies AMD1001, AMD1002, 
A5191, and A5210) using the freebase formulation in normal healthy volunteers and patients with 
HIV. Drug was administered PO in all studies; multiple dose studies were conducted using BID 
dosing. In single and multiple dose escalation studies, maximum concentration (C max) and AUC 
increased more than dose -proportionally over 50 - 400 mg dose range. Mean terminal half -life 
(T1/2) was 22.9 hr, supporting the QD dosing  regimen.  
Steady -state PK parameters were similar in healthy volunteers (AMD -1002) and in HIV infected 
patients (A5210 and AMD -1001). The results  (mean ± standard deviation ) were derived from 26 
subjects, including both healthy volunteers and HIV -infected subjects, who received X4P -001 at 
200 mg BID for 8 to 10 days.  
• AUC(0 -12hr):  3735 ± 1755  nghr/mL  
• Cmax:  1223 ± 600  ng/mL  
• Minimum concentration (Cmin) at 12 hours: 74.3 ± 47.3  ng/mL  
• Time to maximum concentration (Tmax):  2.2 ± 0.9 hr 
For 13 subjects, daily C min(trough) concentrations were determined. Overall, subjects reached steady 
state by [CONTACT_2006] 6, which is consistent with the T 1/2 of ~23 hr. Further, C min and AUC (0-12) were strongly 
correlated suggesting that monitoring C min may provide a practical means for assessing drug 
exposure.  
X4P-001-REGA study was a phase I study in 15 healthy volunteers comparing two different dosing 
regimens: 200 mg BID and 400 mg QD (10 -day treatment). The study was prematurely 
discontinued on Day 3 due to an insufficient number of patients remaining on the trial to assess 
the statistical endpoints. In this study, PK samples were collected from 0 -12 hr for BID dosing  and 
0-24 hr for QD dosing. Preliminary PK results are listed below.  
Following administration of X4P -001 200 mg BID and 400 mg QD on Day 1, the mean Cmax were 
1070 ng/mL and 2662 ng/mL, respectively; the median T max were 2.5 hr and 1.5 hr respectively.  
AUC0-12 was 3682 ng*hr/mL after 200 mg  BID  dose and AUC 0-24 was 9421 ng*hr/mL after 400 
mg QD dose. Comparing with results from Study A5191, the exposure in REGA study is higher.  
[IP_ADDRESS].  Effect of Food on  Absorption  
In a food -effect study (A5191), 9 male subjects received X4P -001 in the fasted stated (fasting 
overnight after midnight until [ADDRESS_15284] -dose) and in the fed state (low fat meal within 30  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
33   
 
minutes prior to dosing), food had a significant negative effect on the bioavailability of X4 P-001. 
Cmax and AUC 0-12 in the fed state was 0.33x and 0.44x of that observed in the fasted state, 
respectively. T max was delayed from 1 hr (fasted) to 3 hr (fed). T 1/2 was not changed.  
[IP_ADDRESS].  Potential for Drug -Drug Interactions Based on CYP Metabolism  
Two clinical studies (A5191, AMD -1002) were conducted to assess the potential for drug -drug 
interactions (DDI). Ritonavir (a strong CYP3A4 inhibitor, P-gp inhibitor) resulted in a modest 
increase in X4P-001 plasma concentrations [A5191 , Cao et al., 2008 ]. The mean Cmax and AUC of 
X4P-[ADDRESS_15285] dose of ritonavir were increased by 39% and 60%, 
respectively, compared to the administration of X4P -[ADDRESS_15286] of X4P -001 on metabolism of CYP3A4 and  CYP2D6 
substrates, using midazolam and dextromethorphan as substrates [ Nyunt et al., 2008 ]. 
Administration of X4P -001 had the following effects.  
• The C max for midazolam (a CYP3A4 substrate) was unaffected; AUC was 1.33x  baseline.  
• The C max for dextromethorphan (a CYP2D6 substrate) was 2.5x baseline; the AUC,  2.86x.  
The magnitude of the midazolam interaction was modest. The magnitude of the effect on 
dextromethorphan has significant potential to result in changes in clinical drug response, affect ing 
either efficacy or toxicity. The clinical study protocols include detailed restrictions on concomitant 
medications to minimize the potential for drug -drug interactions.  
[IP_ADDRESS].  Clinical  Pharmacodynamics  
A primary pharmacodynamic effect of CXCR4 antagonism is mobilization of WBC (including 
both myeloid and lymphoid cells) from the bone marrow into the peripheral circulation. The 
relationship between plasma drug levels and concurrent peripheral blood WBC counts was 
examined in phase 1 studies with dense sampling [Stone et al., 2007 ]. After dosing, circulating 
WBC counts increased from baseline in all subjects, peaking between [ADDRESS_15287] fit 
a sigmoid maximu m exposure (E max) model.  
• The estimated E max was WBC increase to 2.03x baseline (95% confidence interval [CI], 
1.95x to  2.11x).  
• The estimated half maximal effective concentration (EC 50) was 39 ng/mL (95% CI, 28 to 
50 ng/mL), which is below the observed steady -state C min(12h) for X4P -001 at 200 mg BID, 
the starting dose in the proposed oncology  studies.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
34   
 
2.2.3. Clinical Safety Experience with  X4P-001 
[IP_ADDRESS].  Safety Experience – X4 Pharmaceuticals Clinical Development  Program  
As of July 05, [ADDRESS_15288] been initiated or completed:  
• X4P-001-RCCA – the study detailed in this protocol.  
• X4P-001-RCCB - a study adding X4P -001 to patients receiving nivolumab for  treatment 
of advanced  ccRCC.  
• X4P-001-MELA – a phase 1b study of X4P -001 alone and in combination with 
pembrolizumab in patients with advanced  melanoma.  
• X4P-001-MKKA – a phase 2/3 randomized, double -blind, placebo -controlled 
trial of X4P -001 in patients with WHIM (Warts, Hypogammaglobulinemia, 
Infections and Myelokathexis) Syndrome  
• X4P-001-REGA – a phase 1 study in healthy volunteers comparing 2 different dosing 
regimens: 200 mg BID versus 400 mg QD. 
Please refer to the current Investigator’s Brochure for more information related to X4P -001’s 
clinical safety data . 
[IP_ADDRESS].  Safety Experience – Prior Development  Program  
A total of 71 individuals were exposed to X4P -001 in 4 prior clinical studies. Across these 
4 studies:  
• The most common AEs across studies were mild to moderate GI  events.  
• There were no deaths and no discontinuations due to AEs. Two subjects discontinued for 
personal reasons after receiving 1 or 2 doses of  X4P-001. 
• There was one SAE, a grand mal seizure in a subject with a history of epi[INVESTIGATOR_002]; there 
were no events of seizure reported in other subjects. This SAE was the only clinical AE 
assessed as severe (Grade  3). 
• There was one other clinically notable AE. A subject with baseline bradycardia 
experienced an epi[INVESTIGATOR_15964]. The epi[INVESTIGATOR_15965]. There were no events of syncope reported in other  subjects.  
• There were no laboratory abnormalities assessed as clinically significant. The primary 
treatment -related laboratory abnormalities observed were the pharmacologically  expected 
increase in circulating neutroph ils and lymphocytes. Treatment -emergent elevation in 
lipase was observed in one asymptomatic patient; the source of the enzyme (pancreas or 
salivary glands) was  unclear.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
35   
 
• A detailed by -subject analysis of abnormal liver function tests ( LFTs) revealed no pattern 
of treatment -emergent LFT abnormalities suggesting a drug  effect.  
2.2.4. Treatment Effect of X4P -001 in Prior Clinical  Studies  
As of July 05, 2017 , there are no efficacy data with X4P -001 to report in patients with 
malignancy (including ccRCC or melanoma).  
2.2.5. Nonclinical Toxicity Studies of  X4P-[ADDRESS_15289] level (NOAEL) in the 
4-week rat s tudy was 125 mg/kg/day. Adverse effects at 250 mg/kg/day included decreases in 
food consumption, body weight, and reticulocyte counts and minimal bone marrow 
hypocellularity; all except body weight were resolved following a 14 -day recovery period.  
The dose  levels in the 13 -week toxicity study in dogs were 10, 20, 35, and 70 mg/kg/day. 
Microscopic liver findings of pi[INVESTIGATOR_15966]; these findings were typi[INVESTIGATOR_15967]. The NOAEL  
(<10 mg/kg/day) reflected the finding of an isolated focus of liver necrosis (slight) in a single 
male animal dosed at 10 mg/kg/day. None of the remaining 11 an imals (5 males and 6 females) 
in the [ADDRESS_15290] dose levels (35 and 70 mg/kg/day), [ADDRESS_15291] 
microscopic liver changes of multifocal necrosis (minimal to slight), further characterized as 
single cell necrosis in 2 animals. Two of the 12 animals in those dose groups (both  
70 mg/kg/day) showed post -treatment increased ALT, rising to  1.4x above the upper range of 
controls in a male with no histologic findings, and to 2.4x in a female with multifocal single cell 
necrosis (slight). There were no elevations in bilirubin in any animal. One male (35 mg/kg/day) 
had “focally extensive (moder ate)” necrosis and inflammation associated with macroscopic 
discoloration of the liver; transaminases were normal. On review, this lesion was qualitatively 
different from the microscopic multifocal lesions in other animals and had a subcapsular 
location, c onsistent with being secondary to external trauma.  
The original development program of AMD11070 identified an alternative salt form of the drug 
substance for manufacturing purpose, PHB salt (designated AMD11070PHB). Toxicology 
studies of AMD11070PHB includ ed unexpected findings of retinal degeneration in Albino rats 
treated for 26 weeks. This was not seen in Beagles administered either PHB or free base (X4P - 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
36   
 
001) drug forms for up to 13 weeks. AMD11070PHB was never administered to human s and is 
not proposed for use in any clinical studies in this program.  
2.3. Clinical Experience with Related  Compounds  
Mozobil® (plerixafor) is the only approved agent that blocks the CXCR4 receptor, which is an 
injectable drug with a very short half -life, and is approved in combination with granulocyte - 
colony stimulating factor (G -CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral 
blood for collection and subsequent autologous transplantation in patients with non -Hodgkin’s 
lymphoma and multiple  myeloma . 
In tumor models in mice the drug has been administered by [CONTACT_16005]. The results of those nonclinical studies indicate that CXCR4 
receptor blockade has an anti -tumor treatment effect and thereby [CONTACT_16006] X4P -[ADDRESS_15292] demonstrated clinical benefit in patients with 
advanced ccRCC. Targets of multi -tyrosine kinase inhib itors (mTKI) include vascular 
endothelial growth factor receptor (VEGFR), platelet -derived growth factor receptor (PDGFR), 
fibroblast growth factor receptor (FGFR), and cytokine receptor (kit).  
While these agents have demonstrated benefit in progression -free and overall survival, tumors 
typi[INVESTIGATOR_15968] 5 -11 months [ Wang 2011 ]. Consequently, 
strategies to improve or prolong the effects have been actively investigated, including dose - 
intensificat ion, variations in the sequencing and scheduling of agents, and the use of more 
selective agents [ Amato 2007 ; Houk 2010 ; Rini 2011a ; Rini 2011b ]. 
Animal studies of ccRCC xenografts implicate increased infiltration of MDSC as a central factor 
in acquired resistance to VEGF -targeted therapi[INVESTIGATOR_014] [ Panka 2013 ] as well as other anti -cancer 
therapi[INVESTIGATOR_014] [ Shojaei 2007 ; Zea 2005 ; Nagaraj 2007 ; Finke 2011 ]. MDSC trafficking into tumor 
tissue is regulated by [CONTACT_16007], many of which (e.g. SDF-1/CXCL12) are produced in 
response to hypoxia in a HIF -dependent manner. Agents such as X4P -001 that directly block 
CXCL12/CXCR4 signaling should decrease MDSC trafficking and, thereby, prevent the 
emergence of resistance to mTKI. This approach would b e expected to introduce comparatively 
little additional toxicity since CXCR4 -targeted drugs do not induce cell -cycle arrest in normal 
proliferating cell populations and have been well tolerated in short -term (10 -day) clinical studies 
[Moyle 2009 ]. This protocol is designed to test this hypothesis systematically by [CONTACT_16008]4 inhibitor X4P -001 on MDSC trafficking and differentiation, tumor  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
[ADDRESS_15293] use of X4P -001 in patients with RCC.  
3. OBJECTIVES AND  PURPOSE  
 
3.1. Primary  Objective  
The primary objective is:  
• To evaluate the safety and tolerability of escalating dose levels of X4P -001, both in 
combination with axitinib and as single agent, in patients with advanced  ccRCC.  
3.2. Secondary  Objectives  
Secondary objectives are:  
• To assess the treatment effect (clinical ac tivity) of X4P -001, both in combination with 
axitinib and as single agent, in patients with advanced ccRCC using Response  Evaluation 
Criteria in Solid Tumors (RECIST) v1.1 [ Eisenhauer 2009 ], including progression free 
survival  (PFS).  
• To characterize the pharmacokinetics of escalating dose levels of X4P -001 administered 
orally.  
3.3. Exploratory  Objective  
The exploratory objectives are:  
• To investigate associations between the treatment effect of X4P -001 (in combination with 
axitinib and as a single agent) and selected pharmacodynamic and disease -related 
biomarkers (e.g., circulating CD34+ cells, plasma levels of soluble  VEGFR).  
• To assess the treatment effect (clinical activity) of X4P -001, both in combination with 
axitinib and as single agent, in patients with advanced ccRCC using modified Response 
Evaluation Criteria in Solid Tumors  for immune -based therapeutics (iRECIST) 
[Seymour 2017 ]. 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
38   
 
4. STUDY DESIGN AND  ENDPOINTS  
 
4.1. Description of the Study  Design  
This study will be conducted in patients with advanced ccRCC and will comprise 3 parts.  
• Part A  (Phase 1)  will assess the safety and tolerability of escalating doses levels of X4P-
001 in combination with axitinib, a TKI appro ved for use in this setting [ Axitinib US 
prescribing  information, 2014 ]. The X4P -001 dose level for the initial cohort is 200 mg 
BID. Subsequent cohorts will be administered X4P -001 QD. The in itial QD dose level 
will be 400 mg QD (representing the same total daily exposure as 200 mg BID), and then 
progressing to 600, 800, and 1200 mg. A safe maximum tolerated dose (MTD) and/or 
recommended phase 2 dose (RP2D) will be identified in Part A. The RP 2D may be the 
same as the MTD or may be lower (see Section  4.1.1 ). 
• Part B  (Phase 2)  is an expansion cohort assessing the safety, tolerability, and treatment 
effect of X4P -001 at RP2D in combination with axitinib in approximately 45 patients. If 
the RP2D is determined before the MTD is reached in Part A, Part B may be initiated 
while Part A is ongoing (see Section  4.1.2 ). 
• Part C will assess the safety, tolerability, and treatment effect of X4P -001 as 
monotherapy in patients with advanced ccRCC and may be initiated after the MTD of 
X4P-001 with axitinib is defined in Part A. If that MTD was ≤800 mg QD, then the MTD 
as monotherapy will be defined by [CONTACT_15988] -escalation coho rts to receive 
X4P-001 as a single agent up to, but not exceeding, 1200 mg QD (see Section  4.1.3 ). 
4.1.1. Part A (Phase 1) : X4P-001 with Axitinib – Dose -escalation  Cohorts  
Part A will evaluate the safety and tolerability of X4P -001 at increasing dose levels –specifically, 
200 mg orally BID, then 400, 600, 800, 1200 mg QD – in combination with axitinib ( Figure 4 -1). 
Axitinib is given at [ADDRESS_15294] been declared to be safe at a prior Data Review Committee (DRC) meeting to 
better understand the safety, tolerability and PK of X4P -001. 
• Provision is made for a contingency cohort (escalation or de -escalation) receiving an 
additional dose level of X4P-001(e.g. 1000 mg QD) plus axitinib with the approval of the 
Data Review Committee (DRC; see Section  8.6.3 ). 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
39  
 
 
Figure 4 -1: Study Design for Part  A 
 
 
1200 mg QD + axi  
n=3-6 
  
 
 
 
 
[IP_ADDRESS].  Dose Escalation  Process  
 
Dose -escalation will proceed using a standard “3+3” design with careful monitoring and review 
by [CONTACT_16009]. The review will include all available safety data. To facilitate standardizing the 
dose-escalation reviews across different cohorts, the focus will be on the observations at that 
dose level from the start of treatment (C1D1) through the visit scheduled for the beginning of 
C2D1 (Week 5). (Hereafter, this period will be referred to as “the first 4 weeks of treatment”).  
Each dose -escalation cohort is expected to enroll at least 3 patients, with a maximum of 
6 patients.  
• If [ADDRESS_15295] a dose -escalation  review.  
• If [ADDRESS_15296] 4 weeks 
treatment.  
400 mg QD + axi  
n=3-6 
200 mg BID + axi  
n=3-6 
n=3-6 
X4P-001 in Combination with Axitinib (axi) 
Part A - Dose Escalation  
800 mg QD + axi  
n=3-6 
600 mg QD + axi  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
40   
 
• If [ADDRESS_15297] 4 weeks of treatment, 
then no further dosing will occur at that or higher dose levels.  
The expected outcomes of the DRC review include:  
• Dose -escalation – progre ssion to the next planned dose  level.  
• Continued enrollment at the dose level under review (applicable only after 3 patients) – 
enroll up to 6 patients at the current dose level to obtain additional safety data for 
subsequent  review.  
• No further dose -escalation cohorts – at this time the DRC will indicate the dose level 
they consider represents the maximum tolerated dose (MTD) for X4P -001 in combination 
with axitinib.  
• The MTD will be applicable for proceeding to Part C or RP2D is determined to proceed 
to Part  B. 
Replacement of Non -evaluable Patients. A maximum of 6 evaluable patients will be enrolled 
per dose -escalation cohort in Part A. An evaluable patient is defined as a patient who either (a) 
successfully completes [ADDRESS_15298] 75% of the assigned treatment 
(Section 6.1.9 ); or (b) experiences a dose -limiting toxicity (DLT) event in that period.  
To assure that the required number of evaluable patients is available for DRC re view, non - 
evaluable patients (i.e., those who discontinue treatment prior to completion of the C2D1 (Week  
5) visit for reasons other than a DLT) may be replaced within a cohort; the replacement will be 
assigned the same dose level.  
[IP_ADDRESS].  Treatment Cycle 2 and  Beyond  
Patients who do not experience a DLT in Cycle 1 will stay on study treatment. If during Cycle 2 
or later treatment cycles, a patient experiences an unacceptable toxicity (defined with the same 
criteria of DLT for Cycle 1), then, based on the judgment  of the Investigator, the patient may 
continue treatment per dose modification recommendations ( Sections [IP_ADDRESS] and [IP_ADDRESS] ). 
[IP_ADDRESS].  Definition of a Dose -Limiting Toxicity (DLT)  
A DLT event is defined as an adverse event occurring in Cycle 1 (i.e., in the first 4 weeks of 
treatment) that meets both of the following criteria:  
a) Is assessed by [CONTACT_16010] (X4P -001) (see  
Section 8.2.2 for details).  
b) Represents one of the following events (grading as defined by [CONTACT_4652], Ver. 4.03) (see  
Section  8.2.1 ): 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
41   
 
• Is a Grade 3 or Grade 4 clinical  event  
- Exception : Grade 3 nausea, vomiting, or diarrhea lasting <[ADDRESS_15299] received suboptimal medical  management  
• Is a confirmed Grade 3 or Grade 4 laboratory event (confirmatory sample to be submitted 
within 48 hrs of receiving initial lab  report)  
- Exception : Grade [ADDRESS_15300] <72 hrs and do not  require 
hospi[INVESTIGATOR_059].  
- Exception : Grade [ADDRESS_15301]/ALT increases that persist <5 days and with Total 
Bilirubin ≤1.5x  ULN.  
• Results, during the first [ADDRESS_15302] 75% of the intended dose ( Section  6.1.9 ). 
• Is one of the following, which are designated as critical DLT  events  
- AST/ALT increased >3x ULN with Total Bilirubin increased >2x ULN in the 
absence of  cholestasis.  
- Febrile neutropenia (Grade ≥3) — defined as ANC <1000/mm3 with a single 
temperature of >38.3°C (101°F) or a sustained temperature of ≥38°C (100.4°F) 
for more than one  hour.  
- Retinopathy – confirmed treatment -emergent retinopathy (see Section  [IP_ADDRESS] ). 
[IP_ADDRESS].  Definition of Maxi mum Tolerated Dose (MTD) and Recommended Phase 2 Dose 
(RP2D)  
The MTD is the highest dose level meeting both of the following criteria:  
• It is below the level at which [ADDRESS_15303] 4 weeks of treatment;  
• It is a dose level at which no more than [ADDRESS_15304] 4 weeks of  treatment.  
The RP2D is defined as the dose which will be assigned in Part B based on Sponsor and DRC 
review of all av ailable data of X4P -001, including safety and tolerability as well as PK, 
pharmacodynamic, and anti -tumor activity. The RP2D may be the same as the MTD or may be 
lower. The RP2D may not exceed the MTD.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
42   
 
4.1.2. Part B  (Phase 2) : An Expansion Cohort of the RP2D of X4P -[ADDRESS_15305] of X4P -001 at the 
RP2D dose level in approximately 45 patients with advanced ccRCC. If the RP2D is determined 
before t he MTD is reached in Part A, Part B may be initiated while Part A is still ongoing.  
Safety at the RP2D will be verified by [CONTACT_16011]: if ≤ [ADDRESS_15306] patient safety, if additional DLTs are observed 
anytime during the trial, dose de -escalation can be enforced based o n DRC recommendation, or 
the trial can be stopped at the sponsor’s discretion.  
 
Patients in Part B will be followed for safety and tumor response per RECIST 1.1 guidance. 
Patients will remain on study treatment until experiencing disease progression, unacc eptable 
toxicity, or other specified reasons for discontinuation (see Section 5.4.1 ). In addition, a subset of 
patients will have PK/PD evaluations performed (at least 15 patients).  
 
4.1.3. Part C: X4P -001 as a Single Agent  (Monothe rapy)  
The goal of Part C is to assess the safety, tolerability, and treatment effect of single agent X4P - 
001 in patients with advanced ccRCC. Part C may be initiated after the DRC determines the 
MTD for X4P -001 in combination with axitinib  (i.e., may enroll in parallel with Part B); if 
enrollment for Part B closes before the Part C MTD is reached, the Sponsor may elect to 
terminate the study for administrative reasons . 
The MTD of X4P -001 as single agent will be determined as follows:  
• If the MTD in Part A using combination treatment with axitinib is 1200 mg QD, then that 
dose of X4P -001 will be used for the single agent expansion cohort. Higher doses will not 
be assessed.  
• If the MTD in Part A using combination treatment with axitinib is ≤800 mg QD, then 
additional single agent, dose -escalation cohorts – that is, X4P-001 administered alone 
without axitinib – will be enrolled. The starting dose level will be one step above the 
MTD established in combination with axitinib in Part A; the maximum dose eva luated 
will be 1200 mg QD. Escalation will proceed as detailed for Part A; the same potential 
dose levels (Figure 4 -1), the same “3+3” design, and the same dose -escalation review 
procedures will be applied (see Section 4.1.1 ). 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
43  Number of Patients. After establishing the MTD for single agent X4P -001, approximately 15 
patients may be enrolled at that dose level as expansion cohort.  
4.2. Rationale for the Study Design, Including the Choice of Control  Groups  
 
4.2.1. Rationale for the Study  Design  
The open -label study design is consistent with both the study objectives and current principles 
for the evaluation of investigational drugs in patients with advanced malignancy.  
• Part A: The dose -escalation design with  enrollment guided by [CONTACT_16012] a DRC serves to minimize the number of patients required and to  assure 
patient safety is protected.  
• Part B provides assessment of the safety and tolerability of X4P-001 in combination  with 
axitinib at  the RP2D dose level to guide further development of that regimen in the 
treatment of ccRCC and other malignancies. A DRC review of the initial 12 patients 
provides an additional safety assessment of the  RP2D.  
• Part C provides assessing X4P -001 as a single agent to guide further development of 
X4P-001 monotherapy in ccRCC and other  malignancies.  
4.2.2. Rationale for the Dose  Regimen  
Starting dose / Safety. The proposed starting dose (200 mg BID) is selected based on 
experience in prior clinical studies demonstratin g that dose was (a) pharmacologically active 
(Section [IP_ADDRESS] ) and (b) generally safe and well -tolerated in 26 healthy volunteers and HIV - 
infected patients treated for 8 to 10 days ( Section 2.2.3 ), with no treatment -related 
discontinuations and no pattern of significant laboratory abnormalities. See Section 2.2.5 for 
discussion of anticipated clinical exposure relative to findings seen in nonclinical studies.  
Dosing interval. BID dosing is supported by [CONTACT_16013]. In the prior development program, 400 mg BID was generally safe and well tolerated for  
3.5 days and the T 1/2 of X4P -001 is ~23hr. The once daily dosing regimen is easier and more 
reliable, particularly in patients with cancer, for whom avoiding food for two 3 -hour periods each 
day may be difficult.  
In consideration of the advantages of once daily dosing, provision is made for patients in the 
initial cohort adminis tered X4P -001 at 200 mg BID to convert to 400 mg QD, contingent on the 
following:  
• Successful DRC review of the 600 mg QD dose level with approval for further dose 
escalation.  
• Request of the patient’s Investigator and approval of the Medical  Monitor.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
44   
 
Dose Escalation. Dose -escalation will proceed conservatively with increases never exceeding 
1.5x the prior dose level (see Section 4.1.1 ). Conversion of the dose escalation program from 
BID to QD will be  accomplished as follows:  
• Following successful DRC review of the 200 mg BID cohort, once daily dosing regimens 
will be applied to subsequent  cohorts.  
• The first once daily cohort will be 400 mg QD, representing the same total daily dose as 
200 mg BID.  
• Dose escalation will then proceed through the planned daily doses, which will be 
administered as 600, 800, and [ADDRESS_15307] dose level that will 
be given.  
4.3. Endpoints  
4.3.1. Safety Endpoints 
Safety endpoints  are: 
• AEs.  
• Clinical observations  (e.g., vital signs, physical  examination).  
• Laboratory tests, (e.g., clinical chemistry, hematology,  and   thyroid function tests [Part 
A and Part B  only]).  
• ECGs.  
• Ophthalmologic  examination  
4.3.2. Efficacy  Endpoints  
Treatment effect (tumor response) will be analyzed using RECIST v1.1 [ Eisenhauer 2009 ] to 
determine the following efficacy endpoints:  
• Objective response rate (ORR) (Complete Response [CR] + Partial Response  [PR])  
• Time to objective  response  
• Duration of objective  response  
• Disease control rate (CR + PR + Stable  Disease)  
• Time to progression  
• PFS 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
45   
 
4.3.3. PK and PD  Endpoints  
PK samples will be collected from 0 -4hr on Cycle 1 Day 1 (C1D1) and from 0 -8 hr on C1D15. 
Pre-dose PK samples are also collection on C 2D1 and C2D15.  
White blood cell counts and counts of circulation CD34+ positive cells are PD samples.  
 
4.3.4. Exploratory  Endpoints  
Exploratory endpoints are blood biomarkers, including serum biomarkers and PBMC, as well 
as tumor response assessed possibly using modified Response Evaluation  Criteria in Solid 
Tumors  for immune -based therapeutics (iRECIST) [Seymour 2017 ]. 
5. STUDY ENROLLMENT AND  WITHDRAWAL  
 
5.1. Inclusion  Criteria  
Patients must meet all of the following criteria to be eligible for study participation:  
1. Be at least [ADDRESS_15308] one prior course of treatment for ccRCC (see Section 5.2 for 
specific  exclusions).  
5. Have on computed tomography (CT) imaging done within [ADDRESS_15309] v1. 1 [Eisenhauer 2009 ]. See Section [IP_ADDRESS] for 
details regarding specific imaging  technology.  
6. Agree to use contraception as  follows:  
• For women of childbearing potential (WOCP, see Section [IP_ADDRESS] for definition) agree 
to use highly effective contraceptive methods from screening, through the study, and 
for at least [ADDRESS_15310] dose of study drug. Acceptable methods are described 
in Section  [IP_ADDRESS]  
• For males, agree to use a condom with any WOCP sexual partner from Day [ADDRESS_15311] (serum or urine) on 
Day 1 prior to initiating study  treatment.  
8. Be willing and able to comply with this  protocol.  
 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
46  5.2. Exclusion  Criteria  
Patients meeting any of the following criteria are excluded from study participation:  
1. Has life expectancy of less than 3  months.  
2. Has performance status Grade >2 (Eastern Cooperative Oncology Group  [ECOG] 
criteria).  
3. Has [LOCATION_001] Heart Association Class III or IV heart failure or uncontrolled 
hypertension (systolic blood pressure [SBP] ≥160 mm Hg; diastolic blood pressu re 
[DBP] ≥100 mm Hg). 
4. Has previously received  X4P-001. 
5. Parts A and B only : Has received a prior course of  axitinib.  
6. Parts A and B only : Has received mechanistic target of rapamycin (mTOR) inhibitor(s) as 
their only prior treatment for  ccRCC.  
7. Has a prior history or current evidence of intracranial (CNS) metastatic RCC, except  for 
≤3 lesions treated by [CONTACT_15991]  (or any type of radiation)  or excisional surgery, 
clinically stable for at least 4 weeks, and without evidence of recurrence on MRI 
imaging at screening.  
8. Has ongoing acute clinical AEs of National Cancer Institute (NCI) Common 
Terminology Criteria for Adverse Events (CTCAE) Grade >1 resulting from prior  cancer 
therapi[INVESTIGATOR_014] (except alopecia, TKI -related hand -foot syndrome, or thyroid  dysfunc tion).  
9. Has had within the past 6 months the occurrence or persistence of one or more of the 
following medical conditions that could not be controlled with usual medical care (e.g., 
required emergency care or hospi[INVESTIGATOR_059]): hypertension, angina, congestive heart 
failure, diabetes, seizure  disorder.  
10. Has had within the past 6 months the occurrence of one or more of the following events: 
myocardial infarction, cerebrovascular accident, deep vein thrombosis, pulmonary 
embolism, hemorrhage (CTCAE Grade  3 or 4), chronic liver disease (meeting criteria for 
Child -Pugh Class B or C), a second active malignancy (excluding : malignancies that 
were treated curatively and have not recurred within 2 years prior to study treatment; 
completely resected basal cell a nd squamous cell skin cancers; any malignancy 
considered to be indolent and that has never required therapy; and completely resected 
carcinoma in situ of any type ), organ  transplantation.  
11. Has had within the [ADDRESS_15312] during 
the study period, surgery requiring general  anesthesia.  
12. Has a known  history  of a positive  serology  or viral load  for HIV  or a known  history  of 
AIDS.  
13. Has, at screening, serologic laboratory tests meeting one or more of the  following 
criteria:  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
47  • An indeterminate or positive test for antibody to hepatitis C virus (HCV), unless 
documented to have no detectable viral load on 2 independent  samples.  
• A positive test for hepatitis B surface antigen  (HBsAg).  
14. Has, at screening, safety laboratory tests meeting one or more of the  following criteria:  
• Hemoglobin <8.0  g/dL  
• Absolute neutrophil count (ANC)  <1,500/μL  
• Platelets  <75,000/μL  
• Creatinine >2.0x  ULN  
• Serum aspartate transaminase (AST) >2.5x upper limit of normal  (ULN)  
• Serum alanine transaminase (A LT) >2.5x  ULN  
• AST and ALT >5x ULN for patients with liver metastasis  
• Total bilirubin >1.5x ULN (unless due to Gilbert’s Syndrome, total bilirubin >  3.0x 
ULN and direct bilirubin > 1.5x  ULN)  
15. Has received other anti -cancer therapy within the following specified intervals prior  to 
Day 1: 
• TKI within 2  weeks.  
• Radiation therapy within 2  weeks.  
• Bevacizumab within 4  weeks.  
• Other chemotherapy (e.g., mitomycin -C, nitrosourea) or immunotherapy 
(e.g., antibody, cytokine) within 4  weeks.  
• For investigational anti -cancer therapi[INVESTIGATOR_014], the interval will be determined in 
consultation with the Medical  Monitor.  
16. Has, within 2 weeks prior to Day 1, received a medication prohibited based on  CYP3A4 
interaction (see Section [IP_ADDRESS] for details).  
17. Has, within 2 weeks prior to Day 1, received systemic corticosteroids exceeding 
prednisone 10 mg per day or equivalent; for other immunosuppressive agents, the 
exclusionary dose and duration will be determined in consultation with the Medical 
Monitor.  
18. Is nursing.  
19. Has, at the planned initiation of study drug, an uncontrolled  infection.  
20. Has any other medical or personal condition that, in the opi[INVESTIGATOR_689], may 
potentially compromise the safety or compliance of the patient, or may preclude the 
patient’s successful completion of the clinical  study.  
Patients taking medications prohibited on the basis of CYP 3A4 interactions (see Section  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
48  [IP_ADDRESS] ), may, after discussion with the prescribing physician, be changed to a functionally 
equivalent, non -prohibited medication, and, after at least 2 weeks off the prohibited medication, 
reassessed for enrollment, including rescreening, if necessary.  
5.3. Strategies for Recruitment and  Retention  
Following receipt of IRB/IEC approval, t he Investigator may initiate patient recruitment (see 
Section 13). To reach an economically and socially diverse population, the study may be 
announced publicly, including on relevant Internet websites; prior to use, the for m and content of 
such announcements will be submitted to the IRB/IEC for approval (see Section 13). 
5.4. Participant Withdrawal or  Termination  
 
5.4.1. Reasons for Withdrawal or  Termination  
To provide for consistent accounting of patient  disposition, when study treatment is discontinued 
in an individual patient for any reason, the Investigator will complete the appropriate electronic 
case report form (eCRF) and select the primary reason from the following standard categories:  
• DLT event – see Section  [IP_ADDRESS] . 
- For any DLT event occurring during the first 4 weeks of treatment, study treatment 
will be discontinued  permanently.  
- For one of the critical DLT events (see Section [IP_ADDRESS] ) occurring after  successful 
completion of 4 weeks of treatment, study treatment will be discontinued 
permanently.  
- For other unacceptable toxicity (defined with the same criteria of DLT for Cycle 1) 
occurring after successful completion of 4 weeks of treatm ent, provision is made for 
dose reduction (see Sections [IP_ADDRESS] and [IP_ADDRESS] ). 
• Disease progression – Patients will be assessed at study entry and every 8 weeks for 80 
weeks (20 cycles) and then every 12 weeks thereafter while on treatment; unscheduled 
assessments may be conducted in response to new clinical observations. Disease status 
will be classified according to RECIST v1.1 [ Eisenhauer 2009 ] (see Section [IP_ADDRESS] for 
details).  
- Study treatment will be discontinued in patients who demonstrate disease 
progression. For patients who have radiological disease progression, but haven’t 
experienced clinical progression/deterior ation, the patient may stay on study if the 
Investigator considers that the patient may still derive benefit from this study and 
have consulted with Medical  Monitor.  
Removal of the subject for clinical  progression/deterioration will be at the discretion of  
the Investigator. The decision needs to be consulted with Medical  Monitor.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
49  • Adverse Event, other than DLT – This includes any AE (clinical or laboratory; serious or 
non-serious; regardless of relation to study drug), that represents the reason study drug 
was discontinued,  including:  
- The medical judgment of the Investigator based on the best interests of the  patient.  
• The patient’s request based on any  AE. 
• Withdrawal of Consent – The patient desired to withdraw from further participation in the 
study in the absence of a clinical issue. If the patient gave a reason for withdrawing (e.g., 
leaving area), it should be recorded in the eCRF.  
• Lost to Follow -Up – The patient stopped coming for visits.  
• Study Termination – by [CONTACT_1034], for any  reason.  
5.4.2. Handling o f Participant Withdrawals or  Termination  
When study treatment is discontinued for any reason, the End -of-Treatment (EOT) and End -of- 
Study (EOS) visits will be performed as specified. If a patient cannot be seen, attempts will be 
made to contact [CONTACT_16014][INVESTIGATOR_15969].  
5.5. Premature Termination or Suspension of  Study  
The Sponsor reserves the right to terminate the study or particular study center at any  time. If the 
Sponsor or Investigator discovers conditions arising during the study that suggest the study 
should be halted, then study termination can occur only after appropriate consultation between 
the Sponsor and Investigators. Conditions that may war rant study or study center termination 
include, but are not limited to:  
• The discovery  of any unexpected, significant,  or unacceptable  risk to the patients  enrolled 
in the study.  
• Failure of the Investigator to enter patients at an acceptable  rate. 
• Insufficient adherence to the protocol  requirements.  
• A decision on the part of the Sponsor to suspend or discontinue development of  study 
drug.  
Should the study be closed prematurely, all study materials (study drug, etc.) must be returned to 
the Sponsor o r designee (or disposed of as directed by [CONTACT_16015]).  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
50   
 
6. STUDY  DRUG(S)  
 
6.1. Study Drug(s) and Control  Description  
6.1.1. Acquisition  
Study drug will be supplied by [CONTACT_1034]  
 
6.1.2. Formulation, Appearance, Packaging, and  Labeling  
All manufacture, packaging and labeling operations will be performed according to ICH Good 
Manufacturing Practice (GMP) and Good Clinical Practice (GCP) guidelines.  
 
Table 6 -1: Physical and Chemical Properties of Active Ingredient (Drug  Substance)  
Name  X4P-001 
Drug Class  Chemokine (C -X-C motif) receptor 4 (CXCR4) antagonist  
INN Not Assigned  
Molecular Formula  C21H27N5 
Molecular Weight  349.48 amu  
Appearance  white to pale yellow solid  
Solubility  X4P-001 is freely soluble in the pH range 3.0 to 8.0 (>100 mg/mL), sparingly soluble at pH 9.0 (10.7 
mg/mL) and slightly soluble at pH 10.0 (2.0 mg/mL). X4P -001 is only slightly soluble in water.  
Melting Point  111 °C 
 
Table 6 -2: Formulation of Drug  Product  
Name  X4P-001 100 mg or 200 mg Capsule  
Active ingredient  X4P-001 
Excipi[INVESTIGATOR_15970], dibasic calcium phosphate dihydrate, croscarmellose sodium, 
sodium stearyl fumarate, colloidal silicon dioxide, sodium lauryl sulfate  
How supplied  Refer to the Pharmacy Manual . 
Storage  5°C ± 3°C; Protect from light and humidity  
Administration  Oral 
 
6.1.3. Product Storage and  Stability 
Refer to the Pharmacy Manual.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
51   
 
6.1.4. Preparation 
None.  
6.1.5. Dosing and  Administration  
[IP_ADDRESS].  X4P-[ADDRESS_15313] daily dose will be taken in the morning and the second 
daily dose a pproximately 12 hours later using the following guidelines:  
• Dosing should be at the same times each day ± 2  hr. 
• The interval between successive doses should not be <9 hours nor >15 hours. It the 
interval would be >15 hrs, the dose should be omitted and the  usual schedule resumed at 
the next  dose.  
For QD dose, it is expected that the daily dose will be taken as follows:  
• The daily dose should be taken in the morning, at the same times each day ± 2  hr. 
• The interval between successive doses should not be < 20 hrs. 
• If the interval between successive doses is delayed to > 30 hrs, the dose should be 
omitted and the usual schedule resumed the next  day. 
Restrictions relating to food. Absorption is impacted by [CONTACT_16016]:  
• No food or drink (except water) for 1 hour before  dosing  
• No food or drink (except water) for [ADDRESS_15314] effective regimen 
possible.  
[IP_ADDRESS].  Axitinib  
Axitinib may be taken at the same time as X4P -001. Alternatively, since axitinib has been 
associated with GI AEs and its absorption is not altered by [CONTACT_8208] (see current produc t label), 
patients may, with the approval of their Investigator, take the axitinib separately, following the 
same BID dosing schedule guidelines noted in Section [IP_ADDRESS] . 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
52   
 
Investigators should review and b e familiar with the current US prescribing information for 
axitinib.  
6.1.6. Route of  Administration 
X4P-001 will be administered  PO. 
[IP_ADDRESS].  Axitinib  
 
Axitinib will be administered PO.  
 
6.1.7. Dose  Adjustments/Modifications/Delays  
Treatment modifications should be implemented as described below. Any plan to deviate from 
the following guidelines in the interest of patient safety must be previously discussed with the 
Medical Monitor unless there is an urgent need for action. Investiga tors always have the option 
to discontinue study treatment based on their judgment of the patient’s best interests. For dose 
modifications due to concomitant use of strong inhibitors and inducers of CYP3A4, see Section 
7.4.1. 1. 
After dose modification, the reduced doses of X4P -001 and axitinib can be re -escalated to the 
initial assigned dose levels if treatment  related AEs remain ≤ Grade 1 over 4 weeks.  
A patient with a Grade 4 AE may resume treatment at the next lower dose le vel if the AE 
recovers to ≤ Grade 1 and, if in the opi[INVESTIGATOR_15971], the 
patient can be monitored for recurrence of AE.  
[IP_ADDRESS].  X4P-001 Administered in Combination with Axitinib (Part A and Part  B) 
1. Patients will be discontinued from this study if AEs (defined with the same criteria of critical 
DLT event; Section [IP_ADDRESS] ) occur and are considered to be related to  X4P-001. 
 
2. If a patient receiving X4P -[ADDRESS_15315] 4 
weeks of treatment, and subsequently has a unacceptable toxicity (defined with the same 
criteria of DLT for Cycle 1, other than those designated  critical)  
a. And the event is (possibly) related to both X4P -001 and axitinib , study  treatment may be 
managed as  follows.  
• Both X4P -001 and axitinib will be held (dosing interrupted). Note that the Schedules of 
Events are based on calendar days following the first dose and will not  change.  
• If the event does not improve to Grade ≤1 within the next 14 days, study treatment will 
be discontinued.  
• If the event  improves  to Grade  ≤1 within  14 days of holding  study  treatment,  the patient 
may resume axitinib alone at the next lower dose level (see Section [IP_ADDRESS] for axitinib 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
53  dose adjustment  guidelines).  
- If during the first 7 days on axitinib alone at the reduced dose, the event recurs or 
worsens to Grade >2, the dose modification procedure may be applied again, with 
the dose of  axitinib being reduced one additional  level.  
- If during the first 7 days on axitinib alone at the further reduced dose, the event 
recurs or worsens to Grade >2 again, study treatment will be discontinued.  
• If after 7 days on axitinib alone at reduced dose, the event does not recur or worsen, then 
X4P-001 will be resumed at the next lower dose level (see Table  6-3). 
b. And the event is (possibly) related to X4P -001 and not related to axitinib , study  treatment 
may be managed as  follows.  
• X4P-001 will be held (dosing interrupted) without dose modification of  axitinib.  
• If the event does not improve to Grade ≤1 within the next 14 days, study treatment will be 
discontinued.  
• If the event  improves  to Grade  ≤1 within  14 days of holding  study  treatment,  the patient 
may resume X4P -001 at the next lower dose level (Table  6-3). 
• If the event recurs or worsens to Grade >2 at any time, the dose modification procedure 
may be applied again, with the dose of X4P -001 being reduced one additional  level.  
• If there are any further Grade >2 recurrences, study treatment will be discontinued.  
 
c. And the event is (possibly) related to axitin ib, but not X4P -001, dose modification of  axitinib 
is described in Section [IP_ADDRESS] without any dose change for  X4P-001. 
 
Table 6 -3: Dose Modification Levels for  X4P-001 
 
Current Dose (mg)  200 BID  400 QD  600 QD  800 QD  1200 QD  
Modified Dose (mg)  200 QD  200 QD  400 QD  600 QD  800 QD  
 
[IP_ADDRESS].  X4P-001 Administered as a Single Agent (Part  C) 
If a patient receiving X4P -[ADDRESS_15316] 4 weeks of 
treatment, and subsequently has a n unacceptable toxicity (defined with the same criteria of DLT 
for Cycle 1, other than those designated critical), study treatment may, with the agreement of the 
patient, the Investigator, and the Medical Monitor, be managed as follows.  
• X4P-001 will be held (dosing  interrupted).  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
54   
 
• If the event does not improve to Grade ≤1 within the next 14 days, X4P-001 will be 
discontinued.  
• If the event improves to Grade ≤1 within 14 days of holding X4P -001, the patient  may 
resume X4P -001 as single agent at the next lower dose level (see Table  6-3). 
• If the event recurs at Grade >2 at any time after resuming X4P -001, one (and only one) 
additional level of dose reduction may be implemented using t he above  procedure.  
• If there are any further Grade >2 recurrences, study treatment will be discontinued.  
[IP_ADDRESS].  Axitinib  
Dose modifications of axitinib are recommended based on individual safety and tolerability and 
are permitted in this protocol. However, to min imize potential confounding of assessing 
concomitant X4P -001, the guidelines are adapted as follows.  
• Axitinib dose  increases  
- There will be no axitinib dose increases during the first [ADDRESS_15317] week of a cycle after 
completion of all procedures scheduled for the visit that week, including AE and 
con med review, drug compliance, physical exam, and safety laboratory  tests.  
- Dose increases will be done as recommended: Patients must have no AEs Grade  
>[ADDRESS_15318] 2 weeks, be normotensive, and not be receiving anti -hypertensives. 
Dose increases will proceed from 5 mg BID to 7 mg BID to a maximum of 10 mg 
BID.  
• Axitinib dose  decreases  
- These may be made at any time based on the Investigator’s judg ment and 
following the label recommendations – decreasing from 5 mg BID to 3 mg BID to 
2 mg BID.  
- In the event of an unacceptable toxicity (defined with the same criteria of DLT  for 
Cycle 1), dose reduction will be made as detailed  above.  
6.1.8. Duration of  Therapy  
Patients will remain on study treatment until disease progression, unacceptable toxicity, or other 
specified reasons for discontinuation (see Section 5.4). 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
55   
 
6.1.9. Treatment  Compliance  
Treatment compliance will be monitored by 2 procedures.  
• Patients will be provided with a treatment diary to record time and dose taken for both 
X4P-[ADDRESS_15319] food prior to and after dosing X4P-001. 
Diaries will be reviewed with the pa tient at each clinic  visit.  
• Both X4P -001 and axitinib will be dispensed in bottles, which will be examined visually 
at each clinic visit; non -destructive pi[INVESTIGATOR_15972].  
For DLT evaluation, treatment compliance is required for both X4P -001 and axitinib during 
Cycle 1. The percentage of compliance is calculated using the following equation for doses taken 
at the intended dose level:  
% Compliance  = Number of  X4P -[ADDRESS_15320] been taken  
 
6.2. Study Drug Accountability  Procedures  × 100  
Regulatory authorities require accounting of all investigational drug received by [CONTACT_16017]. Records of drug disposition required include the date received by [CONTACT_16018], date 
administered, quantity administered, and the patient to whom study drug was administered. The 
Investigator is responsible for the accountability of all used and unused study drug containers 
and unused study drug. For the Combination Cohort(s), the study center also will maintain 
records for the combination anticancer agent, including the date administered, quantity 
administered, and the patient to whom the agent was administered.  
Each study center is to  use a study drug accountability log to document study drug disposition. 
All items on this form are to be completed in full. The Sponsor’s clinical research associate 
(CRA) is to approve the area where study drug is to be stored and accountability records are to 
be maintained.  
The investigator identification number and patient initials (as allowed by [CONTACT_427]) and 
identification number are to be recorded on each study drug accountability log. Each time study 
personnel dispense study drug for a pati ent, he or she is to record the date dispensed, amount of 
study drug dispensed, and his or her initials. Study personnel are to monitor the inventory of 
clinical supplies and maintain a count of all used and unused study drug. The CRA is to review 
study dr ug accountability records and remaining drug supplies during routine monitoring visits.  
At the completion of the study, the site must obtain written authorization from the Sponsor 
regarding the final disposition of any remaining X4P -001; that disposition m ust be appropriately 
documented. Typi[INVESTIGATOR_15973]:  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
56   
 
• Returning study drug to the  Sponsor.  
• Destroying study drug at the study site according to the site’s institutional  standard 
operating  procedure.  
Supplies of axitinib that have been distributed to the patient should be returned to the study site 
and destroyed as per institutional procedures. Supplies of axitinib that have not been distributed 
may be returned to the Sponsor, destro yed, or used for clinical purposes in accordance with 
institutional procedures. The final disposition will be agreed to in writing between the Sponsor 
and the study site.  
7. STUDY PROCEDURES AND  SCHEDULE  
 
7.1. Study  Procedures/Evaluations  
Written informed consent and, as applicable, assent will be obtained and the consent procedure 
recorded in source documentation before any other study -specific procedures are performed.  
7.1.1. Baseline and Safety  Assessments  
[IP_ADDRESS].  Medical  History  
General Medical History  
A complete medical hist ory is to be documented during Screening, including relevant general 
medical and surgical history, current or past abnormalities or diseases of the following systems: 
allergic (including drug sensitivity), cardiovascular, dermatologic, endocrine/metabolic,  
gastrointestinal, gynecologic, hematologic/lymphatic, hepatic/biliary, immunologic, infectious, 
musculoskeletal, neurologic/psychiatric, renal, and respi[INVESTIGATOR_696].  
The medical history should include all significant illnesses and hospi[INVESTIGATOR_15974] d in 
the past 6 months, whether active or resolved. Illnesses active at the time of informed consent 
will be recorded in the medical history.  
History of Renal Cell Carcinoma (RCC)  
Detailed history of the course of the patient’s RCC will be recorded, includ ing: 
• Prior surgical procedures, diagnostic or  therapeutic.  
• Results (positive and negative) of prior tissue  biopsies.  
• Prior medical treatments (including supportive therapy) – agent, duration, best clinical 
response, adverse events related to treatment, and  reason for  discontinuation.  
• Hospi[INVESTIGATOR_15975] 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
57  malignancy, e.g., systemic infections,  bleeding.  
[IP_ADDRESS].  Enrollment  Procedure  
All patients in this study will be treated open -label. To minimize the pot ential for patients being 
enrolled but not treated, patients will be enrolled (i.e., treatment assigned) as close as feasible  to 
the scheduled date for first dose of study  drug.  
[IP_ADDRESS].  Vital  Signs  
Vital signs include heart rate (HR), SBP, DBP, and temperature. Wh ere feasible, vital signs 
should be measured before blood is drawn and after the patient has been sitting comfortably for 
[ADDRESS_15321] and may be done manually or by  [CONTACT_16019]. Temperature will be obtained 
using an electronic (rapid reading)  device.  
Vital sign measurements will be assessed by [CONTACT_16020] ‘normal’, ‘abnormal, not 
clinically significant’, or ‘abnormal, clinically significant’. Cl inically significant abnormal vital 
sign measurements will be reported as an AE, and, if possible, should be repeated at clinically 
relevant intervals until resolved or stabilized.  
[IP_ADDRESS].  Physical Examination, Body Weight, and  Height  
Complete physical examination s will include measurement of body weight and examination of 
general appearance, skin, neck (including thyroid), eyes, nose, throat, heart, lungs, abdomen, 
lymph nodes, extremities, and nervous system. Body height will be measured at screening only.  
• For pa lpable lymph nodes, the location and maximal linear dimension will be recorded at 
each examination.  
• Examination of the reproductive system, breast, and rectal will be performed if there are 
related symptoms, adverse events, or recent history; the exam may be performed by [CONTACT_16021] a  specialist.  
Physical examination findings will be assessed by [CONTACT_16020] ‘normal’, ‘abnormal, 
not clinically significant’, or ‘abnormal, clinically significant’. Any clinically  significant changes 
identified after the baseline (screening) examination will be recorded as AEs (see Section  8). 
[IP_ADDRESS].  Ophthalmologic Examination  
Ophthalmologic examination will be performed as scheduled and include the following 
elements: assessment of visual acuity (using Snellen test  or local equivalent in countries outside 
the U.S.) , refraction (at screening only), assessment of color vision, slit lamp examination, and 
retinal examination with photographs. All examination reports and pho tographs will be 
submitted to a central repository as soon as feasible after being performed to be reviewed for 
quality and completeness (see study operations manual for details).  Note: an optometrist may 
complete the exam if all requirements can be met, i ncluding use of appropriate equipment to 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
[ADDRESS_15322] designated by [CONTACT_1034].  
[IP_ADDRESS].  ECOG Performance Status  (PS) 
 
The ECOG PS will be obtained by [CONTACT_16022], 
according to the table below.  
 
Table 7 -1: ECOG PS  Definitions  
Grade  ECOG Performance Status  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature, e.g., light house work, office work  
2 Ambulatory and capable of all self -care but unable to carry out any work activities. Up and about 
more than 50% of waking hours  
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking ho urs 
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair  
5 Dead  
[IP_ADDRESS].  Electrocardiogram  (ECG)  
Standard 12 -lead ECG will be obtained after the patient has been semi -recumbent for ~10 
minutes. The following ECG parameters will be recorded: ventricular rate, RR interval, 
PR interval, QRS interval, QT interval, QTc interval, and QTc method.  
7.1.2. Pharmacokinetic  Assessments  
PK samples  (i.e.: “PK dense sampling’)  will be obtained on all patients in Part A and Part C and 
at least 15 patients in Part B as follows:  
• Cycle 1 Day 1: pre -dose ( -30 min); post -dose at 30, 60, 90 min (each ±5 min) and 2, 3, 
4 hr (each ±15  min) 
• Cycle 1 Day 15: pre -dose ( -10 min); post -dose at 30, 60, 90 min (each ±5 min) and 2, 
3, 4, 8 hr (each ±15  min) 
• Cycle 2 Day 1 and Cycle 2 Day 15: pre -dose ( -10 min) 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
59  These visits will be scheduled for early in the day and patients will be instructed to arrive at the 
clinic fasting and having not taken th eir morning dose of study drug(s).  
 
At a minimum, all subjects in Part B should have pre -dose PK samples collected at the visits 
above (e.g. Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 15) if subjects are not 
required to complete the PK dense  sampling.  
All s amples will be analyzed for X4P -001 concentration and some samples in Part B may be 
analyzed to measure axitinib concentration using reversed -phase high performance liquid 
chromatography (RP -HPLC) with tandem mass spectrometry (MS/MS) dete ction.  
7.1.3. Pharmacodynamic  Assessments  
Investigational biomarker and pharmacodynamic assays will be performed by a central 
laboratory designated by [CONTACT_1034]; to maximize consistency, tests may be batched. The 
clinical significance of these tests is unknown at this time, and the results will not be assessed 
by [CONTACT_737].  
[IP_ADDRESS].  Pharmacodynamics  
Whole blood samples will be obtained concurrently with scheduled PK samples on Cycle 1 Day 1 
and Cycle 1 Day 15 only (see above) for:  
• WBC  counts  
• Counts of circulating CD34+ positive  cells.  
PD samples will be obtained on all patients in Part A and Part C and at least 15 patients in Part B.  
If sample yields permit, additional investigational immunomodulatory subsets may be analyzed 
(Table 7-2). PD samples will not be drawn at Cycle 2 Day 1 and Cycle 2 Day 15.  
[IP_ADDRESS].  Blood  Biomarkers  
Blood samples (serum and PBMC) will be collected as scheduled for potential treatment - 
and tumor -related biomarkers that reflect the pharmacologic effects of CXCR4 ant agonism 
on angiogenesis and immunomodulatory subsets of circulating PBMC ( Table 7 -2). 
Additional investigational blood studies may be performed using the collected samples.  
 
Table 7 -2: Candidate Blood  Biomarkers  
Serum factors  associated with angiogenesis 
[DePrimo 2007 ] Immunomodulatory subsets of circulating PBMC 
[Tarhini 2014 ] 
CXCL12 
VEGF -A 
Soluble VEGFR -2 (sVEGFR -2) 
Placenta growth factor (PGF)  Treg lymphocytes  
Activated T cells 
MDSC  
 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
60   
 
7.1.4. Efficacy  Assessments  
[IP_ADDRESS].  Radiologic Assessment of  ccRCC  
Radiologic imaging of chest, abdomen and pelvis for assessing tumor status and treatment effect 
will be performed as indicated in the Schedules of Events. Interim assessments may be done at 
the request of the Investigator based on new findings. Patients enrolled with a history or current 
evidence of CNS disease will have brain imaging by [CONTACT_9252] (MRI) with 
contrast at baseline and, thereafter, as clinically i ndicated.  
Imaging will be interpreted using RECIST v1.1 [ Eisenhauer 2009 ] (see Section [IP_ADDRESS] ). The 
expected imaging technology is CT with slice thickness ≤[ADDRESS_15323]. The use of 
altern ative technologies (e.g., CT scan with slice thickness >5 mm or MRI) requires the approval 
of the Medical Monitor and must be performed in a manner consistent with RECIST. For each 
patient, the imaging modality should be consistent throughout the study. If  there is a need to 
change modality (e.g ., a patient cannot receive radiologic contrast), an alternative modality may 
be used with the approval of the Medical Monitor.  
For clinical management during the study, imaging will be interpreted by [CONTACT_16023] a written report provided. Patients who, in the judgment of the Investigator, have 
Progressive Disease, which is a protocol endpoint, will be reviewed with the Medical Monitor.  
As soon as feasible after an imaging study is performed, the i mages (with indication of the 
modality used) will be submitted to a central repository to be reviewed for quality and for central 
reading; the written report will be submitted to the eCRF.  
For endpoint analysis, after a patient completes the EOT visit, all  imaging studies for that patient 
will be reviewed together and outcomes assigned by [CONTACT_16024]; they will be blinded to treatment allocation and 
clinical outcome.  
[IP_ADDRESS].  Evaluation of Response to Treatment and Disease  Status  
Tumor response assessments will be conducted every 8 weeks (2 cycles) for 80 weeks (20 
cycles) and then every [ADDRESS_15324] v1.1 [ Eisenhauer 2009 ]. Treatment decisions will be made by 
[CONTACT_16025]. For data analysis, scans will be reviewed and interpreted by a blinded central 
review committee comprising up to 3 experienced radiologists; see Section [IP_ADDRESS] for details.  
Patients enrolled with a history or current evidence of CNS disease should have brain imaging by 
[CONTACT_16026], thereafter, as clinically indicated.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
61  The current (v1.1) RECIST provide a detailed process for using sequential CT imaging to 
classify tumor response [ Eisenhauer 2009 ]. Key elements of the process are summarized below;  
details provided in the guideline [ Eisenhauer 2009 ] remain determinative. NOTE: all 
specifications assume use of CT with slice thi ckness ≤5 mm. Modifications are required for 
other technologies [ Eisenhauer 2009 ]. 
Definitions of key terminology:  
• Measurable non -nodal lesions – ≥[ADDRESS_15325]  diameter.  
• Measurable nodal lesions – ≥15 mm in short  axis 
• Nonmeasurable lesions – lesions that are smaller, including those that cannot  be 
measured.  
• Measurable disease – presence of at least one measurable lesion. [NOTE: Entry into this 
study requires at least one measurable extra -renal  lesion.]  
• Target lesions – At baseline, a maximum of 5 measureable lesions, no more than 2 for 
any individual organ, should be identified, documented, and the appropriate diameter of 
each recorded. Lesions should be selected based on size, be representative of disease, and 
be suitable  for reproducible repeat measurement. Target lesions may include measurable 
lymph  nodes.  
• The baseline sum of diameters (SOD) – The sum of the longest diameters for all non - 
nodal target lesions plus the sum of the short axis diameter for all nodal target  lesions.  
• Non-target lesions – All other lesions present at baseline, including pathologic nodes 
(defined as nodes >10 mm in short axis). These should be documented (quantitative 
measurements are not required) so that they can be classified on follow -up as present, 
absent, or unequivocal  progression.  
• New lesions – a new lesion should be unequivocal (e.g., not attributable to variation in 
technique); includes lesions in a location not scanned at  baseline.  
• Definitions of response criteria for target and non -target lesions are summarized in Table  
7-3; these are integrated into an overall response assessment as summarized in Table  7-4. 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
62   
 
Table 7 -3: RECI ST – Definitions of Response Categories for Target  and Non-Target  
Lesions  
Target Lesions   
Complete Response (CR)  (a) Disappearance of all non -nodal lesions, and (b) Absence of pathologic lymph nodes1. 
Partial Response (PR)  ≥30% decrease from baseline in the SOD of the target lesions  
Stable Disease (SD)  Persisting disease that does not meet criteria for either PR or PD  
Progressive Disease (PD)  a) ≥20% increase in the SOD of the target lesions, compared to the smallest sum on study, 
which may be either at baseline or while on treatment;  
and (b) an absolute increase of ≥5 mm in the SOD.  
Non-Target Lesions   
Complete Response (CR)  (a) Disappearance of all non -target lesions, and (b) Absence of pathologic lymph nodes1. 
Non-CR/non -PD Persistence of one or more non -target lesions  
Progressive Disease (PD)  Unequivocal progression of existing non -target lesions.  
1. All lymph  nodes,  whether  or not designated target  or non-target  lesions,  have short  axis diameter  ≤10 mm  
 
Table 7 -4: RECIST – Overall Responses Based on Target Lesions,  Nontarget  Lesions, 
and New  Lesions  
Target 
Lesions  Non-target 
Lesions  New 
Lesions  Overall 
Response  
CR CR No CR 
CR Non-CR/non -PD No  
CR Not evaluated  No PR 
PR Non-PD or not all evaluated  No  
SD Non-PD or not all evaluated  No SD 
Not all evaluated  Non-PD No Non-evaluable  
CR, PR, or SD  PDa No  
PD Any Yes or no  PD 
Any Any Yes  
1. “The designation of overall progression solely on the basis of change in non -target disease” in the face of CR, PR, or  SD of 
target lesions is expected to be “extremely rare” [ Eisenhauer 2009 ]. 
 
[IP_ADDRESS].  Exploratory Analysis of Efficacy Using  iRECIST  
Tumor Response assessments may be explored by [CONTACT_16027] -based therapeutics (iRECIST) [Seymour  2017]. Details of 
this assessment will be defined in statistical analysis pla n (SAP) and/or central imaging review 
documents.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
63   
 
7.2. Laboratory  Procedures/Evaluations  
 
7.2.1. Clinical Laboratory  Evaluations  
The laboratory safety tests below will be performed as scheduled by a central laboratory facility. 
The Investigator  may order  additional  local  laboratory  tests consistent  with their routine  standard 
of care.  
 
Table 7 -5:       Safety Laboratory Tests  
Hematology Panel   
Hematocrit  WBC differential and absolute cell counts:  
Hemoglobin  Basophils  
Platelet count  Eosinophils  
WBC  Lymphocytes  
 Monocytes  
 Neutrophils  
Clinical Chemistry Panel   
ALT  Lipase  
Albumin  Magnesium  
Alkaline phosphatase  Potassium  
Amylase  Total bilirubin**  
AST  Total protein  
Bicarbonate  Sodium  
Calcium  Urea  
Chloride  Uric acid  
Creatine kinase   
Creatinine*   
Glucose    
Inorganic phosphorus    
*Creatinine clearance will be calculated using the method of Cockcroft and Gault (Cockroft, Gault, 1976).  
** If the total bilirubin concentration is above 1.[ADDRESS_15326] bilirubin should be 
differentiated.  
 
Thyroid Function Tests (Parts A and B only)  
Free thyroxin (Free T4)   Thyroid stimulating hormone (TSH)  
Pregnancy tests (WOCP only)*  
beta-human chorionic gonadotropin  
*WOCP are required to take a pregnancy test if their period is late.  
 
 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
64  Serologic tests (Screening only)  
HBsAg   Antibody to HCV  
 
[IP_ADDRESS].  Reporting of Safety Laboratory  Tests  
Results of safety laboratory tests (except serology) are expected to be available to the 
Investigator within 48 hours. Procedures for the Investigator assessment of the results are 
detailed in Section 8.1.5 . Procedures for t he analysis of laboratory data are described in 
Section 8.2.2 . 
[IP_ADDRESS].  Repeating Abnormal Laboratory  Tests  
Laboratory tests showing abnormal or exclusionary values at Screening may be repeated no 
more than once; however, exclusionary serologic results may not be repeated.  
After dosing, abnormal laboratory tests assessed as “clinically significant” values may be 
repeated as often as deemed clinically necessary by [CONTACT_16028].  
7.2.2. Other Assays or Procedures 
None.  
7.2.3. Specimen Preparation, Handling, and  Storage  
Laboratory samples are to be prepared, handled, and stored as instructed in the laboratory 
manual.  
7.2.4. Specimen  Shipment  
Laboratory samples are to be prepared, handled, and stored as instructed in the laboratory 
manual.  
7.3. Study  Schedule  
The overall study schedule is as follows:  
• Screening will be done within 28 days prior to Day 1 (the first dose of study drug). See  
Section [IP_ADDRESS] for details of the enrollment  process.  
• Laboratory tests required for screening will be performed with 14 days prior to Day  1. 
• Treatment is scheduled to be administered continuously. Missed doses will be considered 
skipped.  
• Assessments for treatment response (or disease progression) are scheduled every 8 weeks 
(± 4 calendar days) of treatment for 80 weeks (20 cycles) and every 12 weeks  thereafter.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
65  • The EOT visit is will be performed within [ADDRESS_15327] dose o f study drug or the 
decision to terminate treatment  prematurely.  
• EOS visit, the final study event, will be performed [ADDRESS_15328] 14 
days after th e EOT  visit.  
A detailed schedule of events is presented in Table 1 -1. 
 
7.4. Concomitant Medications, Treatments, and  Procedures  
Prior treatments for ccRCC will be recorded as detailed in Section [IP_ADDRESS] . 
Any concomitant medication used from time of screening through last study visit will be 
recorded in the eCRF, including dose, regimen, and indication (reason for its prescription).  
7.4.1. Precautionary Medications, Treatments, and  Procedures  
[IP_ADDRESS].  Restrictions  related to CYP Interactions  
X4P-001 is metabolized through, and interacts with, the CYP metabolic enzymes found in the 
hepatic and intestinal microsomes (see Section [IP_ADDRESS] for details). Based on these observations, 
the fol lowing restrictions are placed on concomitant medications:  
• Strong inhibitors and inducers of CYP3A4 are prohibited. If a strong inhibitor or inducer 
cannot be avoided, the dose of X4P -001 can be reduced with approval of Medical 
Monitor.  
• Grapefruit and/or s tarfruit products, variable inhibitors of CYP3A4, are  prohibited.  
• Moderate inhibitors and inducers of CYP3A4 are to be prescribed only with the approval 
of the Medical Monitor; additional monitoring of X4P -001 drug levels may be required.  
• Sensitive CYP2D6 substrates should be avoided and other CYP2D6 substrates should be 
administered only with the approval of the Medical  Monitor.  
Appendix S ection 18.[ADDRESS_15329], consultation with the Medical Monitor is 
requested for any concerns about concomitant medication u se. 
[IP_ADDRESS].  Non-childbearing  Potential  
Non-childbearing potential is defined as a female who meets either of the following criteria:  
• Age ≥[ADDRESS_15330] 1 year.  
• Documented hysterectomy, bilateral tubal ligation, or bilateral  oophorectomy.  
[IP_ADDRESS].  Effective Birth Control (Contraception)  Methods  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
66  Women of Childbearing Potential (WOCP) must use a highly effective method of contraception 
during the study and through [ADDRESS_15331] dose of study drug. Acceptable methods 
include:  
• hormonal contraceptiv es when used with an additional barrier method (e.g., a  male 
condom):  
o combined (estrogen and progestogen containing) hormonal  contraception 
associated with inhibition of  ovulation  
▪ oral 
▪ intravaginal  
▪ transdermal  
• progestogen -only hormonal  contraception  associated  with inhibition  of ovulation:  
o oral 
o injectable  
o implantable  
• intrauterine device  (IUD)   
• intrauterine hormone -releasing system  (IUS)  
• bilateral tubal  occlusion  
• vasectomized partner who has received a medical assessment of surgical success  (when 
the p artner is the sole  partner)  
• sexual abstinence (when in agreement with the lifestyle and preference of the WOCP)  
Males are required to use a condom with any WOCP sexual partner from Day [ADDRESS_15332] dose of study drug.  
7.4.2. Prohibited Medications, Treatments, and  Procedures  
The exclusion criteria specify treatments prohibited at the time of study entry ( Section 5.2). 
While patients are receiving study treatment, other treatments for ccRCC are prohibited. Patients 
who discontinue treatment prematurely and have completed the End -of-Treatment visit, may 
receive available or investigational treatment for their disease at any time based on the judgment 
of their physician. If  such treatment is initiated prior to the EOS visit, this will be recorded in 
concomitant medications and considered in assessment of any new AE.  
7.4.3. Prophylactic Medications, Treatments, and  Procedures 
None.  
7.4.4. Rescue Medications, Treatments, and  Procedures  
[IP_ADDRESS].  Trea tment of Expected Adverse  Events  
Based on prior clinical experience (as detailed in Section 2.2.3 ), the following treatments are 
recommended for symptomatic relief of “red eye”, “dry eye”, nasal congestion (in some 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
67  instances with nosebleed), and facial pains, which may occur within 48 hours of initiation of 
treatment:  
• Lubricant eye drops containing carboxymethylcellulose sodium (0.5%), such as 
Refresh™  Tears  
• Non-medicated saline nasal spray, such as Simply Saline™ Nasal Mist ( Arm &  Hammer)  
• Acetaminophen  (Tylenol™)  
7.4.5. Precautions Regarding  Axitinib  
Drug metabolism. Axitinib is metabolized primarily by [CONTACT_097]3A4 and 3A5 and to a lesser extent 
by [CONTACT_097]1A2 and CYP2C19. Co -administration of strong CYP3A4 inhibitors and inducers, and  of 
grapefruit or starfruit products, is prohibited.  
• The requirements detailed in Section [IP_ADDRESS] are consistent with this. Administration of 
X4P-[ADDRESS_15333] increase in exposure to midazolam (also a CYP3A4 
substr ate). 
Exclusions: Moderate to severe hepatic impairment; pregnancy.  
• Both of these are also exclusions under this  protocol.  
Warnings and Precautions. The following events are listed: hypertension and hypertensive 
crisis; arterial thromboembolism; venous thr omboembolism; hemorrhage; cardiac failure; 
gastrointestinal perforation; thyroid dysfunction; wound healing complications; reversible 
posterior leukoencephalopathy syndrome; proteinuria.  
• None of these events was observed in prior studies using X4P -001. Rec ent uncontrolled 
hypertension, uncontrolled congestive heart failure, and thromboembolic events are all 
exclusions.  
Elevation of liver enzymes. Grade 1 and 2 elevations of ALT (up to 5x ULN) were observed in  
~20% of patients with advanced RCC treated with axitinib. The incidence of Grade 3/4 events 
was <1%.  
• LFTs are being monitored closely in this protocol, and clinically significant  abnormalities 
are explicitly defined ( Section  [IP_ADDRESS] ). 
7.4.6. Patient Restrictions during the Conduct of the  Study  
In the interest of their safety and to facilitate assessment of both safety and treatment effect, the 
patients participating in this study will be requested to agree to the following restrictions during 
the study:  
• Not start any new pre scription medications, except as prescribed or approved by  [CONTACT_16029];  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
68  • Not take any over -the-counter medications, except as instructed or approved by  [CONTACT_16030].  
• Not drink grapefruit juice or eat grapefruit/st arfruit.  
• Use effective contraception as defined in Section  [IP_ADDRESS] . 
7.5. Appropriateness of  Measurements  
Planned assessments are standard measurements for this type of study and are considered 
appropriate. Per regulatory guidance , demographic data, complete medical histories, including  
cancer treatment history, and Baseline disease status are to be documented for all patients at 
Baseline ( FDA Guidance for Industry 2001 ). 
AEs and SAEs are monitored in this study in accordance with International Conference on 
Harmonisation (ICH) GCP guidelines to ensure the safety of patients. Furthermore, additional 
safety assessments conducted during this study, including physical examinations, ECGs, vital 
signs ass essments, and clinical laboratory tests, are widely used and generally recognized as 
reliable, accurate, and relevant. These tests and procedures also will be monitored in accordance 
with ICH GCP guidelines.  
Tumor response and progression will be assessed using standard criteria for the assessment of 
disease response in solid tumors, RECIST, v1.1.  
 
8. ADVERSE  EVENTS  
 
8.1. Definitions  
8.1.1. Adverse Events  (AE)  
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceut ical product, and which does not necessarily have to have a causal 
relationship with this treatment. An AE can therefore be any unfavorable and unintended sign 
(including abnormal laboratory findings), symptom, or disease temporally associated with the 
use of an investigational product, whether or not related to the investigational product.  
An AE in a clinical study may be any of the following:  
• An unfavorable and unintended symptom reported by [CONTACT_102]. Patients will be 
encouraged to report treatment -emergent AEs spontaneously; general, non -directed 
questioning may also be used to elicit reports of  AEs.  
• Clinical sign detected by [CONTACT_737]. Observations by [CONTACT_16031].  
• Abnormal result fro m a laboratory study or other diagnostic procedure that meets at  least 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
69  one of the following  criteria:  
- Results in termination of study  drug;  
- Leads to treatment;  
- Leads to further diagnostic tests (other than a single repeat for  confirmation);  
- Is assessed as “clinically significant” by [CONTACT_16032].  
8.1.2. Serious Adverse Events  (SAE)  
An AE or suspected adverse reaction is considered serious if, in the view of either the 
Investigator or Sponsor, it:  
• Results in death.  
• Is life -threatening. Life -threatening means th at the patient was at immediate risk of death 
from the reaction as it occurred, i.e., it does not include a reaction which hypothetically 
might have caused death had it occurred in a more severe  form.  
• Requires in -patient hospi[INVESTIGATOR_1081]. 
Hospi[INVESTIGATOR_6930]/or surgical operations scheduled to occur during the  study 
period, but planned prior to study entry are not considered AEs if the illness or disease 
existed before the patient was enrolled in the stu dy, provided that it did not deteriorate in 
an unexpected manner during the study (e.g., surgery performed earlier than planned). 
Additional exclusions to SAE reporting include hospi[INVESTIGATOR_15976]: 
- Elective  procedures.  
- Social/administrative reasons in the absence of an  AE. 
- Expected deterioration caused by [CONTACT_16033].  
• Results in persistent or significant disability/incapacity. Disability is defined as a 
substantial disruption of a person’s ability to conduct normal life functions.  
• Is a congenital anomaly/birth  defect.  
• Is an important medical event. An important medical event is an event that may not result 
in death, be life-threatening, or require hospi[INVESTIGATOR_15977], based upon appropriate m edical judgment, it may jeopardize the patient and may 
require medical or surgical intervention to prevent one of the outcomes listed in the 
definitions for SAEs. Examples of such medical events include allergic bronchospasm 
requiring intensive treatment in an emergency room or at home, blood dyscrasias or 
convulsions that do not result in in-patient hospi[INVESTIGATOR_059], or the development of drug 
dependency or drug  abuse.  
 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
[ADDRESS_15334] related to any dose should be 
considered adverse drug reactions. The phrase "responses to a medicinal products" means that a 
causal relationship between a medicinal product and an adverse event is at least a reasonable 
possibility, i.e., the relationship c annot be ruled out.  
8.1.4. Suspected, Unexpected Serious Adverse Reaction  (S[LOCATION_003]R)  
A S[LOCATION_003]R is defined as an SAE that meets both the following criteria with respect to study drug:  
• Suspected — is assessed as related or possibly related to study drug (see Section  8.2.2 ); 
• Unexpected — compared to the study drug -related AEs described in Investigator’s 
Brochure, the event meets any of the following  criteria:  
- The event was not previously  described;  
- The event is now characterized as more severe (see Section  8.2.1 ); 
- The event is now characterized more specifically (e.g., an event of “interstitial 
nephritis” in a patient receiving an agent previously described as associated with 
“acut e renal  failure”).  
In clinical studies involving ill patients, events considered related to the natural history of the 
disease under study or to lack of efficacy (that is, the event is considered more likely related to 
those factors than to other factors, including study drug) are not considered "unexpected".  
8.1.5. Clinical Laboratory Adverse  Events  
The Investigator will review the results of all Safety Laboratory tests (see Section 7.2.1 ) and 
designate any results outside of the reference range as either of the following:  
• Abnormal, not clinically significant  (NCS)  
• Abnormal, clinically significant  (CS).  
In making this judgment, the Investigator will consider all available information, incl uding the 
patient’s clinical condition, all available laboratory results, and the potential for false positive test 
results. In addition, laboratory studies that result in the actions specified in Section 8.1.1 will be 
class ified as “abnormal, clinically significant”.  
Any result assessed as “abnormal, clinically significant” will be recorded as an AE unless it is 
consistent with one or more of the following:  
• Process noted in the medical  history:  
• Ongoing adverse event already  recorded;  
• Expected course of the primary disease under  study.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
71  8.2. Classification of Adverse  Events  
 
8.2.1. Severity  
The intensity (synonym: severity) of clinical AEs (i.e., symptoms reported by [CONTACT_5363]/or 
signs observed by [CONTACT_737]) will be assessed b y the Investigator using the NCI CTCAE 
(v4.03) five -level grading system, available on -line (see 
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 -06-14_Qu ickReference_8.5x11.pdf ). 
If the AE is not included in the NCI CTCAE, then the Investigator is to determine the intensity 
of the AE according to the following criteria:  
• Mild (Grade 1):  AE that disappears or is easily tolerated on continuation of study  drug.  
• Moderate (Grade 2) : AE sufficiently discomforting to cause interference with usual 
work  activities.  
• Severe (Grade 3): AE that is incapacitating, with inability to work or perform daily 
activities.  
• Life-Threatening (Grade 4):  AE that is potentially l ife threatening.  
• Death (Grade 5):  Death related to  AE. 
8.2.2. Grading of Laboratory Safety Tests for Reporting and  Analysis  
Treatment -emergent abnormal laboratory results will be reported as AEs when assessed as 
“clinically significant” using the procedures and criteria detailed in Section 8.1.5 . 
For purposes of analyzing laboratory data, all lab oratory results will be graded using NCI CTCAE 
v4.03 and then summarized as “shift tables” comparing baseline and treatment -emergent results. 
This process will assure that the final study report contains complete and consistent analyses of 
safety laborator y tests.  
8.2.3. Relationship to Study  Drug  
This determination is based on the Investigator’s clinical judgment regarding the likelihood that 
the study drug caused the AE and may include consideration of some or all of the following 
factors:  
• Alternative possible c auses of the AE, including the patient’s underlying disease  or 
co-morbid conditions, other drugs, other host and environmental  factors;  
• Temporal sequence between the exposure to study drug and the  AE; 
• Whether the clinical or laboratory manifestations of the AE are consistent with  known 
actions or toxicity of the study  drug;  
• Whether the AE resolved or improved with decreasing the dose or stoppi[INVESTIGATOR_10098] 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
72  drug (i.e., dechallenge); or recurred or worsene d with re -exposure to the  drug 
(i.e., rechallenge).  
The relationship between the study drug and the AE will be described using one of the following 
categories:  
• Related:  the study drug is more likely the cause of the AE than other factors;  
• Possibly related: there is a reasonable possibility that the study drug is the cause of the 
AE, including that the study drug and another factor(s) are equally likely as causes of the 
AE; 
• Unlikely related: another factor is considered more likely the cause  of the AE than the 
study  drug;  
• Not related:  another factor is considered to be the cause of the  AE. 
Related and possibly related AEs may result during the use of the study drug as planned (per 
protocol), or from abuse, withdrawal or over -dosage of the agent.  
8.2.4. Expectedness  
AEs meeting the criteria in Section 8.1.[ADDRESS_15335] apparent. Table 8 -1 summarizes the basis for 
reporting the date and time of onset for the different types of AEs.  
 
Table 8 -1: Reporting the Date and Time of Onset of AE for Different Types of  Events  
Type of Event  Examples  Source of Date and Time of Onset  
Symptom  Headache, fe verish, paresthesia  When first experienced by [CONTACT_16034] (Finding)  Elevated BP, enlarged liver on physical exam  When first observed by [CONTACT_16035] / 
diagnostic result  Neutropenia, hyperglycemia, 
lesions on brain  scan When lab sample was obtained or diagnostic study 
performed  
 
The time of onset of symptoms may be appreciably earlier than the date and time the Investigator 
becomes aware of the event. Some events may be apparent to the patient and Investigator 
independently, and information from each may contribute to the final report. For example, a 
patient may report the onset of a rash 2 days before being seen by a physician who makes a 
diagnosis of herpes zoster based on appearance and laboratory confirmation. I n that case, there is 
a single AE, with the date of onset based on the date of the initial observation by [CONTACT_5363] 
a specific description (herpes zoster) based on the clinical examination and  tests.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
73   
 
8.2.6. Actions Taken for Management of AE 
AEs will be followed and managed by [CONTACT_737], including obtaining any supplemental 
studies needed to define the nature and/or cause of the event (e.g., laboratory tests, diagnostic 
procedures, consultation with other health care professionals).  
For each AE the Investigator will categorize as follows the actions taken to manage the AE:  
• Concomitant medication — one or more medications (prescription or over -the-counter) 
were started or increased in dose; non -medication actions may also have been  ordered.  
• Other action — only non -medication action(s) were ordered as management of the  AE 
(e.g., bed placed in Trendelenburg  position).  
• No action — no actions were ordered for management of the  AE. 
8.2.7. Follow -up and Outcome of  AEs 
If possible, AEs will be followed until resolved (synonyms: recovered, recuperated, ended) either 
with or without sequelae, including for patients who prematurely discontinue study participation. 
For AEs that are assessed as not drug -related and are not re solved at the EOS visit, follow -up 
may be limited with the approval of the Medical Monitor.  
The outcome of each event will be described using the following categories:  
• Resolved without sequelae — the event resolved and patient returned to  baseline;  
• Resolve d with sequelae — the event resolved but the patient is left with residual 
problems (e.g., functional deficits,  pain);  
• Resolving — at the last observation, the event was  improving;  
• Not Resolved — at the last observation, the event was  unchanged;  
• Death (Fatal) — to be used for the one AE which, in the judgment of the Investigator, 
was the primary cause of  death;  
• Unknown — there were no observations after the onset (initial observation or report) of 
the event.  
Note: Resolving and Not Resolved may al so be used for AEs that were unresolved at the time a 
patient died, but were not assessed as the primary cause of death.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
74   
 
8.2.8. Date and Time of Outcome  
For each class of outcome as defined above, Table 8 -2 indicates the date and time to be recorded. 
As discussed in detail for date / time of onset (see Section 8.2.5 ), determining the date / time an 
event resolved (ended) should reflect the type of event and the source of the in formation.  
 
Table 8 -2: Date and Time of Outcome for AE by [CONTACT_16036] (with or without sequelae)  Date and time event observed or reported as resolved  
Death  Date and time of death  
Resolving or Not Resolved  Date and time of last observation  
Unknown  None (see definition above)  
 
8.3. Time Period and Frequency for Event Assessment and  Follow -Up 
Procedures for the collection and recording of AEs are as follows:  
• From obtaining informed consent through EOS, there will be active surveillance to 
identify all AEs. Events will be recorded in the AE portion of the eCRF, with particular 
attention to whether the onset of the event was before or after the administration of  the 
first dose of study  drug.  
• After EOS, surveillance will be passive (only events brought to the Investigator’s 
attention will be considered) and only events assessed as S[LOCATION_003]Rs (see Section 8.1.4 ) 
will be recorded.  
8.4. Reporting  Procedures  
8.4.1. Adverse Event  Reporting  
Each patient must be carefully monitored for the development of any AEs. This information 
should be obtained in the form of non -leading questions (e.g., “How are you feeling?”) and from 
signs and symptoms detect ed during each examination, observations of study personnel, and 
spontaneous reports from patients.  
All AEs (serious and non -serious) spontaneously reported by [CONTACT_5363]/or in response to an 
open question from study personnel or revealed by [CONTACT_16037], physical examination, or other 
diagnostic procedures occurring within the time frame specified in Section 8.3 will be 
documented in the patient’s source documents and recorded in the eCRF. Any clinically relevant 
(as det ermined by [CONTACT_737]) deterioration in laboratory assessments or other clinical  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
[ADDRESS_15336] be recorded in the patient’s source documents and in the 
eCRF.  
The AE term should be reported in standard medical terminology when possible. Also when 
possible, signs and symptoms indicating a common underlying pathology should be noted as one 
comprehensive event. For each AE, the investigator will evaluate and report the onset, 
resolution, intensity,  causality, action taken, serious outcome (if applicable), and whether or not 
it caused the patient to discontinue the study.  
8.4.2. Serious Adverse Event  Reporting  
SAE reporting, including supporting materials, will be performed by [CONTACT_16038] a system 
approv ed by [CONTACT_1034]; detailed training will be provided during site initiation. Contact 
[CONTACT_16039].  
[IP_ADDRESS].  Procedures for Reporting SAEs to the  Sponsor  
The initial notification of each SAE will be reported within 24 hours of the time the Investigator 
(or the Investigator's designee) becomes aware that the event has occurred and will include the 
following items of information (any items not available should be explicitly noted):  
• Protocol number, study site, patient  number;  
• Investigator’s name, address, and contact [CONTACT_3031] (phone, fax, email);  
• Description of the event (i.e., date and time of onset, initial assessment, treatments  and 
course);  
• Current status of the patient and the  event; 
• Criteria by [CONTACT_16040];  
• Date of the first administration of study  drug;  
• Date of the last administration of study drug prior the  event;  
• Assessment of relationship of study drug to the  event;  
• Whether the study drug was discontinued or adjusted as a result of the  event.  
A narrative summary of the event will be reported within [ADDRESS_15337] in understanding the event, e.g., relevant medical history, co -morbid 
conditions, physical exam, diagnostics, assessment, treatments (including concomitant 
medications), response to treatment, course, and outcome (if known).  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
76   
 
Thereafter, signed supplemental (follow -up) information will be provided as it becomes 
available to the Investigator (either directly or as a result of investigation into a query). Such 
information includes but is not limited to:  
• Copi[INVESTIGATOR_15978] — including diagnostic procedures (e.g., laboratory 
tests), surgical procedures, and  consultations  
• More definitive outcome for events previously reported as ongoing or unknown  outcome  
[IP_ADDRESS].  Requirements for Expedited and Periodic Reporting of Adverse  Events 
S[LOCATION_003]Rs are required to be reported rapi[INVESTIGATOR_15979]/IECs (typi[INVESTIGATOR_15980] 7 days for fatal or life -threatening S[LOCATION_003]Rs; within 15 days for all other S[LOCATION_003]Rs). The 
Sponsor and the Investigator will work together to meet these  reporting requirements.  
[IP_ADDRESS].  Notification of SAEs to the Investigator by [CONTACT_16041], the Sponsor will notify the Investigator of the 
occurrence of S[LOCATION_003]Rs reported by [CONTACT_16042]. The Investigator will promptly inform his/her IRB/IEC of such communications 
from the Sponsor and will document that notification in the Investigator’s Regulatory Binder.  
8.4.3. Events of Special  Interest 
None.  
8.4.4. Reporting of  Pregnancy  
Pregnancies occurring in the patient or patient’s partner while the patient is receiving study drug 
or within 1 month after the patient’s last dose of study drug will be reported using the same 
procedures as for SAEs described in Section 8.4.[ADDRESS_15338] be discontinued immediately in the event of a pregnancy in the patient. The 
patient should be referred to an obstetrician/gynecologist experienced in reproductive toxicity for 
further evaluation and counseling.  
The Investigator will follow the patient / patient’s partner until completion of the pregnancy, and 
must notify the Medical Monitor of the outcome within 5 days. The Investigator will provide  this 
information as a follow -up to the initial  report.  
If the outcom e of the pregnancy meets the criteria for immediate classification as an SAE (i.e., 
spontaneous abortion [any congenital anomaly detected in an aborted fetus is to be documented], 
stillbirth, neonatal death, or congenital anomaly), then the Investigator sh ould report it as such. 
Furthermore, all neonatal deaths that occur within 30 days of birth should be reported, without  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
[ADDRESS_15339] to causality, as SAEs. In addition, any infant death after 30 days that the Investigator 
suspects is related  to the in -utero exposure to the study drug should also be reported.  
8.5. Study Halting  Rules  
Stoppi[INVESTIGATOR_15981], 
including delivery procedure, appear during the study.  
The study also may be  stopped based on a decision on the part of the Sponsor to suspend or 
discontinue development of study drug.  
8.6. Safety  Oversight  
8.6.1. Procedures for Monitoring Risks Associated with  X4P-001 
Table 8 -3 indicates specific procedures in  this protocol for managing these previously identified 
risks.  
 
Table 8 -3: Monitoring Procedures for Risks Identified in Prior Studies  of X4P-001 
(AMD11070)  
Prior Findings  Clinical Monitoring Procedures  
X4P-001 is predominantly metabolized through CYP -3A4a Avoid concomitant medications that are strong CYP3A4 
inhibitors or inducers; If a strong inhibitor or inducer can not 
be avoided, the dose of X4P -001 can be reduced with 
approval of Medical Monitor.  
X4P-001 is a moderate inhibitor of CYP -2D6a1 Avoid sensitive CYP2D6 substrates. Closely monitor other 
CYP2D6 substrates  
Beagles, 13 -week toxicology study with X4P -001 (free -base)2 
-- ALT: mild (1.4x –2.4x), exposure -related increases  
-- Total bilirubin: no increases in any animal  
-- Microscopic liver findi ngs: multifocal necrosis (single cell) in 4 
of 12 animals dosed at 35 or 70 mg/kg/d  Safety laboratory tests, including aspartate transaminase, 
alanine transaminase, total bilirubin, every 4 weeks during 
treatment.  
Rats, 26 -week toxicology study with AMD11070PHB (salt)c3 
-- retinal degeneration (20, 50, 100 mg/kg bid)  
-- retinal atrophy (100 mg/kg BID only)  An ophthalmology evaluation every 12 weeks: 
visual acuity assessment; color vision assessment;  
slit lamp exam; retinal examination with photographs.  
1. A detailed listing of agents with potential for CYP -related interaction is provided in Appendix Section  18.2. 
2. The liver findings in beagles treated for 13 weeks with the PHB salt were greater than those observe d with the free base 
drug. This (and all prior) clinical studies use only the free base drug.  
3. The retinal changes were observed only in albino rats treated for 26 weeks with the PHB salt. No retinal changes were 
observed in beagles treated for 13 weeks wit h either the free base or the PHB  salt. 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
78   
 
8.6.2. Additional Procedures for Monitoring Patient Safety 
Additional procedures for patient safety are summarized  below:  
• The first dose of study drug will be administered by [CONTACT_3462]; in Part A, the 
patients will be observed over the next several hours while PK samples are  obtained.  
• Ongoing monitoring for adverse  events.  
• Regularly scheduled safety laboratory  tests.  
• Ongoing monitoring of all concomitant medications (prescription and over -the-counter) 
to avoid potential drug -drug-interactions mediated through alterations in CYP - 
metabolism.  
• Detailed procedures for monitoring and review during dose -escalation,  including:  
- Constitution of a DRC to make recommendations regarding dose -escalation and 
determination of the MTD ( Section  8.6.3 ). 
- Definitions for DLT events ( Section  [IP_ADDRESS] ) 
- Definition for MTD ( Section  [IP_ADDRESS] ). 
- DRC will also review the data from the first 12 patients participating in Part B to 
confirm the safety of the RP2D selection ( Section 4.1.2 and 8.6.3  ). 
• Detailed provisions for management of study drug in individual patients based on safety, 
tolerability, and disease response. In brief, each enrolled patient is planned to receive 
study treatment until the earliest  of: 
- DLT event – see Section  [IP_ADDRESS] . 
- Disease progression – based on CT imaging scan results or as prompted by  [CONTACT_16043], symptoms, and laboratory findings, and classified according to RECIST 
v1.1 [ Eisenhauer 2009 ](see Section [IP_ADDRESS] for details).  
8.6.3. Data Review Committee  (DRC)  
Members of the DRC will have appropriate experience treating patients with advanced ccRCC 
and/or conducting early phase studies of investigational drugs and will include the following:  
• An independent physician not otherwise involved with the  study.  
• The Medi cal Monitor for the  study.  
• Participating  Investigator(s).  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
79   
 
• A physician representative of the Sponsor. 
The functions of the DRC  are: 
• Perform the dose -escalation review (see Section  [IP_ADDRESS] ). 
• Make specific recommendations for the progress of the study, including confirming  the 
RP2D selection in Part B by [CONTACT_16044] (see Section  4.1). 
• Determine the MTD (see Section  [IP_ADDRESS] ). 
The DRC comprises experienced clinicians, who will make recommendations based on their 
judgment. In consideration of the dynamic nature of early phase studies, those recommendations 
may include alternative courses of action not anticipated here.  
9. CLINICAL  MONITORIN G 
 
9.1. External Review of the Study Conduct at Participating  Sites  
All study -related materials at the site are subject to external review to ensure the safety of the 
patients, the integrity of the study data, and compliance with all applicable regulatory and 
oversight requirements.  
There are several different classes of review:  
• Monitoring — review by [CONTACT_16045], typi[INVESTIGATOR_15982] (CRO) coordinating the clinical conduct of the study. As 
detailed belo w, visits may be conducted before, during, and after the conduct of the 
study.  
• Audits — systematic, independent review by [CONTACT_16046], potentially from an organization not involved  in 
the clinical conduct of the  study;  
• Regulatory review — performed by [CONTACT_16047].  These 
authorities may be from the country where the site is located or from another  country.  
Monitoring and auditing visits on behalf of the Sponsor will be scheduled with the Investigator 
in advance and will be conducted at a reasonable time. To facilitate these visits, the Investigator 
will assure that the follow ing are available:  
• Appropriate space, facilities and access to all source documents (including access  to 
computerized records either electronically or as complete print  outs).  
• Consent/assent forms, eCRFs, SAE forms, and medical records for all screened and  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
80  enrolled  patients.  
• Timely access to site personnel, including the Investigator, sub Investigator(s), and  other 
study personnel on the day of the visit to resolve any questions that  arise.  
Regulatory authorities may visit and review the site and/or Investi gator during or after the study 
and may or may not notify the Investigator or the Sponsor in advance. The Investigator will fully 
cooperate with regulatory audits conducted at a reasonable time in a reasonable manner. The 
Investigator will notify the Spons or immediately of any contact [CONTACT_16048].  
 
9.2. Study Monitoring  Visits  
 
9.2.1. Site Qualification and Initiation  Visits  
Before an investigational site can enter a patient into the study, a representative of X4 will visit 
the site to perform the following:  
• Inspect the facilities (e.g., clinical and administrative areas, pharmacy,  laboratory).  
• Discuss with the Investigator(s) and other personnel their responsibilities with regard s 
to protocol adherence, as well as  the responsibilities of X4 and its  representatives.  
• Review the site trial master file (TMF), including documentation related to the protocol, 
the Investigator, and other study site personnel; correspondence to and from the  IRB/IEC 
the Sponsor, and their  representatives.  
• Review the standard operating procedures and current practices relating to clinical  and 
pharmacy activities, data handling, the IRB/IEC oversight and the informed consent 
process.  
9.2.2. Interim Monitoring  Visits  
During the study, a CRA from or re presenting X4 will visit the investigational site, for the 
following:  
• Provide information and support to the  Investigator(s).  
• Confirm that facilities remain  acceptable.  
• Confirm that the investigational team is adhering to the protocol, that data are being 
accurately recorded in the case report forms, and that investigational product is being 
appropriately handled and  accounted.  
• Perform source data verification, including verifying the data in the eCRFs against  the 
relevant source documents (see Section 11.3) and resolving any discrepancies  noted.  
• Record and report any protocol  deviations.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
81  • Confirm that AEs and SAEs have been properly documented on eCRFs; that any  SAEs 
have been forwarded to X4; and that SAEs meeting criteria for reporting have been 
forwarded to the  IRB/IEC.  
Between visits the CRA will be available as needed to provide information or support to the 
Investigator(s) or other staff.  
9.2.3. Study Closeout  Visit  
The study will be considered complete when all of the followi ng have occurred:  
• All treated patients have completed all scheduled visits plus any unscheduled  follow -up 
required by  [CONTACT_2695];  
• All eCRFs have been completed, submitted and all queries  resolved;  
• The study database has been  locked.  
• The Sponsor or designee will then conduct a study closeout visit, which may include, but 
is not limited to, the  following:  
• Review the site TMF to assure all required regulatory documents are current  and 
complete.  
• Resolve any open issues from prior monitoring, audit or inspection  visits.  
• Review the site’s provisions for meeting the requirements for retention study  records.  
• Discuss possible future site  audits.  
• Review the Sponsor’s publication  policy.  
• Confirm compliance with requirements for notifying the IRB/IEC of study events, 
including  closure.  
• Collect any unused study materials for either return to the Sponsor or disposal in a 
manner approved by [CONTACT_16049].  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
82   
 
10. STATISTICAL  CONSIDERATIONS  
 
10.1. Statistical and Analytical  Plans  
A detailed statistical analysis plan (SAP) will be developed. The SAP will define populations for 
analysis, outline all data handling conventions, including software, and specify additional 
statistical methods to be used for analysis of safety, efficacy and pharmacokinetics.  
Consistent with the primary objective, the study design represents a pragmatic assessment of 
safety and tolerability across different dose levels of X4P -[ADDRESS_15340] are intended to guide further development of X4P -001 and aid in the 
design of appropriately controlled studies.  
10.2. Statistical  Hypotheses  
Not applicable.  
 
10.3. Analysis  Datasets  
Analyses will be performed using the following populations:  
• Safety / Intent -to-Treat (ITT) Population — all patients who received at least one dose of 
study  drug.  
• PK – all patients who have at least one evaluable concentration . 
• Clinically Evaluable Population –All patients who receive at least one dose of study 
medication, who have  at least one valid post -baseline response (CR/PR/SD/PD), and 
have  no major protocol deviations  which will impact the efficacy assessment .  
The clinically evaluable population may be om itted from the final analysis if clinically 
evaluable and ITT population  are similar and there are  no clinically meaningful 
differences in outcomes between the 2 populations.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
83   
 
10.4. Description of Statistical  Methods  
 
10.4.1.  General  Approach  
Study events will be recorded using the calendar date and (where applicable) the time to the 
nearest minute.  
For purposes of post -study analysis (e.g., tables and listings), study days will be designated as 
follows:  
• Day [ADDRESS_15341] dose of study  drug.  
• The days prior to Day 1 are designated Day –1, Day –2, etc; there is no Day 0. 
• The days following the day of the first dose of study drug are designated Day 2, Day 3, 
etc. 
• The day of each dose of study drug is indicated by [CONTACT_16050] "L", e.g., if the 
last dose is administered on Day 43, it will be displayed as "Day  43L".  
• The days following the last administration of study drug are designated Day 1P, Day 2P, 
etc. 
The times of events related to dosing of s tudy drug will be designated as minutes or hours before 
or after the time of dosing, which is designated as t = 0 (zero). Thus, 15 minutes prior to dosing 
is t = –15 min; 2 hour after dosing is designated t = 2 h.  
Missing and partial dates will be imputed.  Full details will be given in the SAP. 
Missing baseline data will be imputed with screening data where available. No further 
imputations of missing data will be made.  
10.4.2.  Baseline Descriptive  Statistics  
Descriptive statistics will be used to summarize demogr aphics and baseline characteristics. In 
addition, a summary will be presented for patient disposition, including number of patients 
enrolled into and completing each study part.  
Medical history, medications used prior to treatment, and concomitant medicati ons will be 
summarized by [CONTACT_16051].  Please refer  to the  SAP for details.  
10.4.3.  Analys es of Safety  Endpoint  
The primary objective of the study is safety and tolerability. AEs will be coded using Medical 
Dictionary for Regulatory Activities (MedDRA) version 16.0 (or later) and tabulated by [CONTACT_15992], 
grade, and relationship to study therapy. Laboratory results, vital signs, and ECG parameters will 
be summarized using descriptive statistics. Laboratory values will also be graded according to
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
84  NCI CTCAE, Version 4.03, and summarized in shift tables. DLT events will be listed and 
summarized.  
Safety observations will be analyzed using descriptive statistics and tabulation. No formal 
statistical comparisons are planned. All safety data will be pres ented in listings.  
10.4.4.  Analysis of the Efficacy  Endpoint(s)  
The secondary objective of treatment effect (tumor response) will be analyzed using RECIST 
v1.1 criteria [ Eisenhauer 2009 ] as identified by [CONTACT_16052]:  
• ORR (CR + PR) 
• Time to objective  response  
• Duration of objective  response  
• Disease control rate (CR+PR+ Stable  Disease)  
• Time to progression  
• PFS 
Analysis of Tumor response, ORR and Disease Control Rate (DCR) will be tabulat ed using Best 
overall response, by [CONTACT_15994], incorporating 95% exact Clopper -Pearson confidence intervals 
(CI) for ORR and disease control rate. . The analysis will be based on intent -to-treat (ITT) and 
Clinically Evaluable patient populations.  
Duration of ORR will be summarized as median (with 95% CI) and interquartile range estimated 
using Kaplan -Meier method with corresponding 95% CIs.  
Median time to objective response, TTP, PFS as well as the proportion of patients with PFS at 6 
and 12 months (with 95 % CI) will also be derived from Kaplan -Meier estimates.  
Tumor Response and endpoints listed above may also be explored by [CONTACT_16053] -based therapeutics ( iRECIST) [ Seymour 
2017 ].  Details of the analysis plan will be defined in  the SAP.  
10.4.5.  Planned Interim  Analyses  
There is no formal provision for an interim analysis in this early phase study.  
 
10.4.6.  Multiple Comparison/Multiplicity 
Not applicable.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
85   
 
10.4.7.  Tabulation of I ndividual Response  Data  
The individual response data will be provided in patient data listings and the details will be 
described in SAP.  
10.4.8.  Exploratory  Analyses  
The details of exploratory analyses will be described in SAP.  
 
10.4.9.  Pharmacokinetic  Analyses  
PK data will be analyzed (a) by [CONTACT_16054], C max, 
and T max, and (b) across dose levels testing for dose proportionality of AUC and C max. 
10.5. Sample  Size 
The maximum numbers of patients planned to be enrolled in Parts A and C are as follows:  
• Part A, Dose -escalation: 6 patients per dose level (5 planned dose  levels)  
• Part B, A RP2D expansion cohort: approximately 45 patients will be enrolled;  
• Part C, Dose -escalation (to be done only if the MTD for X4P -001 from Part A 
(combi nation treatment) is ≤800 mg QD): up to 6 patients per single agent dose - 
escalation level (maximum 3 dose  levels);  
• Part C, Expansion: maximum 15  patients  
Dose -escalation in Part A (and, if needed, in Part C) employs the standard 3+3 design. Table  
10-1 presents the probability of escalation from a lower dose to the next higher dose, for true  
rates of DLT ranging from 10% to 90%. For example, if the true DLT rate were 0.20 (20%), then 
the chance  of dose escalation would be 0.71 (71%).  
 
Table 10 -1: Relationship between Underlying DLT Rate and Probability  of Dose 
Escalation  
Underlying DLT Rate  10% 20% 30% 40% 50% 60% 70% 80% 90% 
Probability of Dose Escalation  91% 71% 49% 31% 17% 8% 3% 1% 0.1%  
 
In Part B, approximately 45 patients will be enrolled and dosed with X4P -001 in the combination 
of axitinib to provide a preliminary assessment of both safety and anti -tumor activity. With 45 
subjects at the RP2D, the two -sided 90% confidence interval width for any binary response rate 
(e.g., DLT or binary PD markers) will be approximately 0.24, assuming a 40% response rate. If a 
dose de -escalation occurs after the first 12 patients, the remaining 33 patients will be dosed at a  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
86   
 
lower dose  level. With 33 patients, the confidence interval width will be approximately 0.28 for a 
binary response rate.  
Safety at RP2D will be verified by [CONTACT_16011]: if ≤ [ADDRESS_15342] patient safety, if additional DLTs are observed 
anytime during the trial, dose de -escalation can be enforced based on DRC recommendation, or 
the trial can be stopped at the sponsor’s discretion.  
In Part C, dose -escalation (if needed after Part A) cohorts of X4P -001 as single agent 
(monotherapy) will employ the traditional 3+3 design. When the pote ntial MTD is identified, an 
expansion cohort of approximately  15 patients will used to further assess MTD. With 15 
subjects, there is a 79% chance of observing at least one AE with the true underlying rate of 
10%, and a 54% chance of observing at least one  AE with true underlying rate of 5%.  
10.6. Measures to Minimize  Bias 
10.6.1.  Enrollment/ Randomization/ Masking  Procedures  
No randomization or blinding methods will be employed in this study.  
 
10.6.2.  Evaluation of Success of Blinding 
Not applicable.  
10.6.3.  Breaking the Study Blind/Participant Code 
Not applicable.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
87   
 
11. SOURCE DOCUMENTS AND ACCESS TO  SOURCE 
DATA/DOCUMENTS  
Source documents are the originals of any documents used by [CONTACT_737], hospi[INVESTIGATOR_307], or 
institution that verify the existence of the patient  and substantiate the integrity of the data 
collected during the study.  
11.1. Medical  Records  
Medical records related to the patient’s routine clinical care, including prior to or during the 
study:  
• Information obtained from the patient’s personal physicians or o ther third  parties 
regarding the patient’s medical history or prior physical  condition.  
• Medication prescription and administration  records.  
• Laboratory  reports,  including  clinical  pathology  and diagnostic  histologic  pathology.  
• Reports of imaging  studies.  
• Data and reports from automated instruments (e.g., vital  signs).  
• Medical records relating to scheduled and unscheduled clinical  visits  
11.2. Study -Specific Source  Documents  
Study -specific source documents include, but are not limited to, the following:  
• The informed consent form, signed and dated by [CONTACT_102].  
• The site screening  log. 
• Any clinical reports noted above that are scheduled as part of the protocol and have  been 
annotated to indicate the significance of any abnormal  findings.  
• Concomitant medic ation prescription and administration  records.  
• Records relating to scheduled and unscheduled study visits, including, but not limited to, 
results of examinations, observations relating to AEs, and  concomitant medications.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
88   
 
11.3. Source Docume nts Requirements  
The following document characteristics are essential to assuring data quality and are required of 
all documents generated by [CONTACT_16055].  
• Be prepared at the time of the events or activities described (i.e.,  contemporaneously);  
• Indicate both the date and time  recorded;  
• Identify the source of all recorded information (e.g., the patient, direct observations of  the 
recorder, laboratory reports, external / historical  sources).  
• Text should be readable and unambiguous, including application of best medical record 
practices (e.g., minimal use of abbreviations; proper numerical, dose and posology 
formats).  
Electronic health record systems must be compliant with current regulatory require ments for 
systems containing “protected health information”, including, but not limited to:  
• Security requirements for restricted access and electronic  signatures  
• Electronic  timestamp  
• Audit trails for  any changes or amendment 
Paper documents must meet the following  requirements:  
• Be written legibly in dark (preferably black) ink, including signature [CONTACT_16068].  
• Be signed (or initialed), with date and time, by [CONTACT_16056]. The site must maintain a 
formal log showing for all study personnel printed name, full s ignatures, and  initials.  
• In the event that any entry needs to be changed, a single line will be made through the 
original entry, the correct information entered (or referenced) on the same page, and the 
action initialed, dated, and (if appropriate) explained. The original entry must not be 
obscured or obliterated by [CONTACT_16057] -out, correction fluid or overlay of other 
material.  
Study -specific source document forms created by [CONTACT_16058].  
11.4. Electronic Case Report Forms  (eCRFs)  
The Sponsor will provide a regulatory -compliant electronic data capture (EDC) system for 
reporting study data to a central facility holding the study database. All study per sonnel will be 
trained on the system and each will have a unique login password and electronic signature.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
89   
 
The Investigator (or qualified sub -Investigator approved by [CONTACT_1034]) will review all eCRFs 
and indicate their concurrence by (electronic) signature.  
12. QUALITY ASSURANCE AND QUALITY  CONTROL  
 
12.1. Study  Monitoring  
Monitoring and auditing procedures developed by [CONTACT_16059], in 
order to comply with ICH GCP guidelines, as described in Section 9.2. 
12.2. Case Report Form  Completion  
The Sponsor or designee will provide the study centers with eCRFs for each patient.  
eCRFs will be completed for each study patient. It is the Investigator’s responsibility to ensure 
the accuracy, completeness,  and timeliness of the data reported in the patient’s eCRF. Source 
documentation supporting the eCRF data should indicate the patient’s participation in the study 
and should document the dates and details of study procedures, AEs, and patient status.  
The Investigator, or designated representative, should complete the eCRF as soon as possible 
after information is collected, preferably on the same day that a patient is seen for an 
examination, treatment, or any other study procedure. Any outstanding entries must be 
completed immediately after the final examination. An explanation should be given for all 
missing data.  
The Investigator must electronically sign and date the Investigator’s Statement at the end of the 
eCRF to endorse the recorded data.  
12.3. Computerize d Systems / Medical Records as Source  Data  
All study data recorded on source documents are to be transcribed into the eCRFs. Any 
electronic study data are to be entered into a secure, validated data processing system and a 
backup maintained. Any changes to  electronic study data will be documented.  
12.4. Audits and  Inspections  
Authorized representatives of Sponsor or designee, a regulatory authority, or IRB/IEC may visit 
the study center to perform audits or inspections, including source data verification. The pur pose 
of a Sponsor audit or inspection is to systematically and independently examine all study -related 
activities and documents to determine whether these activities were conducted, and data were 
recorded, analyzed, and accurately reported according to the  protocol, ICH GCP, and any 
applicable regulatory requirements.  
The investigator should contact [CONTACT_12559] a regulatory agency 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
90  about an inspection.  
12.5. Resolution of  Deficiencies  
The Investigator agrees to take promptly any reasona ble steps requested by [CONTACT_16060] a result of monitoring, audits, inspections, protocol 
deviations, or review of any other study documentation. Failure to take adequate remedial action 
can result in suspension or termination of the study at the site.  
13. ETHICS/PROTECTION OF HUMAN  SUBJECTS  
 
13.1. Ethical  Standard  
The Sponsor and any third party to whom aspects of the study management or monitoring have 
been delegated will undertake their assigned roles for this study in compliance with all applicable 
industry regulations, the ethical principles stated in the Declaration of Helsinki, and ICH GCP 
Guideline E6.  
ICH GCP Guideline E6 is available at:  
https://www.fda.gov/downloads/drugs/guidances/ucm073122.pdf  
13.2. Institutional Review Board/Independent Ethics  Committee  
The IRB/IEC will review all appropriate study documentation in order to safeguard the rights, 
safety, and well -being of the patients. The stu dy will only be conducted at study centers where 
IRB/IEC approval has been obtained. The protocol, Investigator’s Brochure, informed consent, 
advertisements (if applicable), written information given to the patients (including diary cards), 
safety updates,  annual progress reports, and any revisions to these documents will be provided to 
the IRB/IEC by [CONTACT_737].  
The final study protocol, including the final version of the Informed Consent Form, must be 
approved or given a favorable opi[INVESTIGATOR_15983]/IEC as appropriate. Written IRB/IEC 
approval must be received by [CONTACT_16061] a site can enroll any patient into the 
study.  
The Investigator is responsible for informing the IRB/IEC of any amendment to the protocol in 
accordanc e with local requirements. In addition, the IRB/IEC must approve all advertising used 
to recruit patients for the study. The protocol (and other amended study documents) must be re - 
approved by [CONTACT_1201]/IEC upon receipt of amendments and annually, as local regulations require. 
The Investigator is also responsible for providing the IRB/IEC with reports of any reportable 
serious adverse drug reactions from any other study conducted with the investigational product. 
The Sponsor will provide this information to the Investigator.  
Progress reports and notifications of serious adverse drug reactions will be provided to the 
IRB/IEC according to local regulations and guidelines.  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
91   
 
13.3. Informed Consent  Process  
 
13.3.1.  Consent/assent and Other Informational Documents Provided to Participants  
The Investigator(s) at each center will ensure that the patient is given full and adequate oral and 
written information about the nature, purpose, possible risk and benefit of the study. Patients 
must also be notified that they are free to discontinue from the study at any time. The patient 
should be given the opportunity to ask questions and allowed time to consider the information 
provided. This process should be recorded in the p atient’s source documentation.  
The patient’s signed and dated informed consent must be obtained before conducting any study 
procedures. Documentation of the consenting process must be recorded in the patient’s source 
documents.  
13.3.2.  Consent Procedures and  Docum entation  
The Investigator(s) must maintain the original, signed Informed Consent Form. A copy of the 
signed Informed Consent Form must be given to the patient, and this must be documented in the 
patient’s source documents.  
13.4.  Participant and Data  Confid entiality  
In order to maintain patient privacy, all eCRFs, study drug accountability records, study reports, 
and communications will identify the patient by [CONTACT_10573] (as allowed by [CONTACT_427]) and the 
assigned patient number. The Investigator will g rant monitor(s) and auditor(s) from the Sponsor 
or its designee and regulatory authority(ies) access to the patient’s original medical records for 
verification of data gathered on the eCRFs and to audit the data collection process. The patient’s 
confidenti ality will be maintained and will not be made publicly available to the extent permitted 
by [CONTACT_4913].  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
[ADDRESS_15343]  KEEPI[INVESTIGATOR_1645]  
 
14.1. Data Collection and Management  Responsibilities  
All study data recorded on source documents are to be transcribed into the eCRFs. Any 
electronic study data are to be entered into a secure, validated data processing system and a 
backup maintained. Any changes to electronic study data wil l be documented.  
14.2. Study Records  Retention  
The Investigator will maintain all study records according to ICH GCP and applicable regulatory 
requirement(s). Records will be retained for at least [ADDRESS_15344] or according to applicable regulatory requirement(s). If the Investigator withdraws from 
the responsibility of keepi[INVESTIGATOR_8090], custody must be transferred to  a person willing to 
accept the responsibility. The Sponsor must be notified immediately by [CONTACT_16062] e -mail and 
the notification confirmed in writing if a custodial change occurs.  
14.3. Protocol  Deviations  
A protocol deviation is defined as an event in which  the Investigator or site personnel did not 
conduct the study according to the Protocol, including compliance requirements and agreements. 
Guidelines for minor procedural variations (e.g., collection time of blood samples) will be agreed 
to and documented by [CONTACT_16063]. Events 
conforming to those guidelines will not be considered deviations.  
For protocol deviations relating to individual patients, the event and relevant circumstances will 
be recorded on sour ce documents and on the appropriate eCRF; reported to the Sponsor in a 
timely manner; and presented in the Clinical Study Report.  
Deviations that are not patient -specific (e.g., unauthorized use of an investigational agent outside 
the protocol, either human administration or laboratory use) will be reported to the Sponsor in 
writing and copi[INVESTIGATOR_15984].  
Deviations that can be anticipated should, if possible, be discussed with the Sponsor before being 
implemented.  
14.4. Publication and Data Sharing  Policy 
X4 recognizes the importance of communicating the results of scientific studies, including 
clinical studies, and, therefore, encourages their publication in reputable scientific journals and 
presentation at seminars or conferences. X4 also has legitim ate corporate and shareholder  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
93   
 
responsibilities, including, but not limited to, protecting confidential information about its 
proprietary products and obtaining patent protection for its intellectual property.  
Therefore, the following procedures apply to any communication (including written, oral, or 
electronic; manuscript, abstract, other publication, or presentation) of results or information 
arising from this study (including any ancillary studies i nvolving study patients) to any third 
parties:  
• The proposed communication will be prepared in collaboration with the  Sponsor.  
• The final proposed version must be submitted to X4 for review and comment at least 
30 days prior to presentation, submission for p ublication or other  dissemination.  
• In the event X4 reasonably determines that a proposed communication  contains 
confidential or patentable material, they may require either of the  following:  
- The material be removed from the  communication;  
- The communication be delayed for up to [ADDRESS_15345] policy is addressed in the Clinical Trial Agreement.  
  
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
94   
17. LITERATURE  REFERENCES  
 
ACTG (DIAIDS) Pr otocol A5210. Unpublished data. See Section 5.2.1 for details.  
Amato RJ, Harris P, Dalton M, Khan M, Alter R, Zhai Q, Brady RJ, Jac J, Hauke R, Srinva S: A 
Phase II trial of the intra -patient dose -escalated sorafenib in patients (pts) with metastatic renal  
cell cancer (mRCC) [abstract]. J. Clin Oncol 2007; 25(18S; June 20 Supplement):5026.  
Cao YJ, Flexner CW, Dunaway S, et al. Effect of Low -Dose Ritonavir on the Pharmacokinetics 
of the CXCR4 Antagonist AMD070 in Healthy Volunteers. Antimicrob Agents Chemoth er. 
2008;  52:1630 -1634.  
Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0, 28 May 2009. U.S. 
Department of Health and Human Services, National Institutes of Health, National Cancer 
Institute. NIH Publication No. 03 5410.  
DePrimo SE, Bello  CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic 
activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and 
VEGF -related proteins. J Translational Med 2007;  5:32.  
Ehtesham M, Stevenson CB, Thomp son RC. [Letter] Preferential Expression of Chemokine 
Receptor CXCR4 by [CONTACT_16064]. Neurosurgery 2008;  63:E820  
Eisenhauer EA,Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: 
Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;  45:[ADDRESS_15346] Activation Protein and 
Escape from Immune Surveillance Cancer Immunol Res 2014;  2:187 -193. 
Feig C,  Jones JO, Kraman M, et al. Targeting CXCL12 from FAP -expressing carcinoma 
associated fibroblasts synergizes with anti –PD-L1 immunotherapy in pancreatic cancer. PNAS 
2013;110: [ZIP_CODE] -[ZIP_CODE]  
Finke J, Ko J Rini B, Rayman P, Ireland J, Cohen P. MDSC as a mechan ism of tumor escape 
from sunitinib mediated anti -angiogenic therapy. Int Immunopharmacol 2011; 11: 856 -61. 
Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ: Relationship between 
exposure to sunitinib and efficacy and tolerability endpoints in p atients with cancer.  
INLYTA® (axitinib) tablets for oral administration. US FDA prescribing information. August 
2014.  
Kioi M, Vogel H, Schultz G, et al. Inhibition of vasculogenesis, but not angiogenesis, prevents 
the recurrence of glioblastoma after irrad iation in mice. J Clin Invest. 2010;  120:694 –705. 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
[ADDRESS_15347] poor survival in 
resected pancreatic adenocarcinoma. Br J Cancer 2009;100: 1444 -1451.  
Motzer RJ, Escudier B, Bukowski R, et al. Prognostic factors for survival in 1059 patients 
treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer 2013;  108:[ADDRESS_15348] Dis. 2009;  48:798 –805 
Nagaraj S, Gupta K, Pi[INVESTIGATOR_15985] V, Kinarsky L, Sherman S, Kang L, Herber DL, Schneck J, 
Gabrilovich DI. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in 
cancer. Nat Med 2007; 13: 828 -35 
NCI CTCAE v4.03, 14 June 2010 available at (accessed 6 April 2015): 
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 -06-14_Q uickReference_5x7.pdf . 
Nishino M, Giobbie -Hurder A, et al. Developi[INVESTIGATOR_007] a common language for tumor response to 
immunotherapy: immune -related response criteria using unidimensional measurements. Clin 
Cancer Res. 2013;  19:[ADDRESS_15349]. 2008;  47:559 -565. 
Panka DJ, Liu Q, Geissler AK, Mier JW. HDM2 antago nism delays the development of sunitinib 
resistance in RCC xenografts: Effects of MI -319 on sunitinib -induced p53 activation, SDF -1 
induction, and tumor infiltration by [CONTACT_398]11b+/Gr -1+ myeloid suppressor cells. Mol Cancer 2013; 
12: 17.  
Parameswaran R, Yu M, G roffen J, Heisterkamp N. Combination of drug therapy in acute 
lymphoblastic leukemia with a CXCR4 antagonist. Leukemia 2011;  8:1314 -23 
Righi E, Kashiwagi S, Yuan J, et al. CXCL12/CXCR4 Blockade Induces Multimodal Antitumor 
Effects That Prolong Survival in an Immunocompetent Mouse Model of Ovarian Cancer.  Cancer 
Res 2011;  71:[ADDRESS_15350] 2011a;103(9) :763-773. 
Rini BI, Schiller JH, Fruehauf JP, et al, Diastolic blood pressure as a biomarker of axitinib 
efficacy in solid tumors. Clin Cancer Res 2011b;17(11)3841 -9. 
Sekiya R, Kajiyamo H, Sakai K, et al. Expression of CXCR4 indicates poor prognosis in pati ents 
with clear cell carcinoma of the ovary. Human Pathology. 2012;  43:904 -910. 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
[ADDRESS_15351]: guidelines for response criteria for use in 
trials testing immunotherapeutics.  Lancet Oncol. 2017;18:e143 -e152  
Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber HP, Ferrara N. 
Tumor refractoriness to anti -VEGF treatment is mediated by [CONTACT_398]11b+Gr1+ myeloid cells. Nature 
Biotech 2007; 25: 911 -20. 
Staller P, Sulitkova J, Lisztwan J, et al. Chemokine receptor CXCR4 downregulated by [CONTACT_16065] –Lindau tumour suppressor pVHL. Nature 2003;  425:[ADDRESS_15352] SB, Flexner C, et al. Multiple -Dose Escalation Study of the Safety, 
Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor 
Inhibitor, in Human Subjects. Antimicrob Agents Chemother.  2007;51(7):2351 –2358.  
Tarhini AA, Edington H, Butterfield LH, et al. Immune Monitoring of the Circulation and the 
Tumor Microenvironment in Patients with Regionally  Advanced Melanoma Receiving 
Neoadjuvant Ipi[INVESTIGATOR_125]. PLoS One 2014;9(2):  e87705.  
Turner KJ, Moore JW, Jones A, et al. Expression of Hypoxia -inducible Factors in Human Renal 
Cancer: Relationship to Angiogenesis and to the von Hippel -Lindau Gene Mutation. Ca ncer Res. 
2002;  62:2957 -2961.  
[LOCATION_002] Department of Health and Human Services, Food and Drug Adminstration. 
Guidance for Industry: Cancer Drug and Biological Products — Clinical Data in Marketing 
Applications, 2001. Available at: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/u  
cm071323.pdf . Accessed:  15 December 2016.  
Wang X, Zhang L, Goldberg SN, et al. High dose intermittent sorafenib shows improved 
efficacy over conventional continuous dose in renal cell carcinoma. J Translat Me d. 2011;  
9:220 - 227. 
WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human 
Subjects, 19 October 2013. Available at (accessed 6 April 2015) https://www.wma.net/policies -
post/wma -declaration -of-helsinki -ethical -principles -for-medical -research -involving -human -
subjects  
Wolchok J, Hoos A, et al. Guidelines for the evaluation of immune thera py activity in solid 
tumors: immune -related response criteria. Clinical Cancer Research 2009;15: 7412 -7420.  
Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, 
Quiceno D, Youmans A, O’Neill A, Mier J, Ochoa AC. Arginase -producing myeloid suppressor 
cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005; 65: 
3044 -8. 
X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)   
97   
 
18. APPENDICES  
 
18.1. Revision History and Sponsor  Signature  
[CONTACT_16069] 18 -1. Significant revisions made in each protocol 
version are provided in a separate Summary of Changes document.  
 
Table 18 -1: Protocol Revision  History  
Ver. 
No. Date  Comment  
1.0 7 Apr 2015  Initial release – submitted with IND  
2.[ADDRESS_15353] 1.1  
4.0 3 Mar 2016  Updated safety experience; technical corrections  
5.0 20 Jun 2016  Changed dose regimen from BID to QD, added clinical PK 
data supporting QD dosing, and updated sample size 
justification section.  
6.0 01 Feb 2017  Change Part B study design  
6.1 23 Feb 2017  South Korea  specific  amendment only.  Fixed errors in Table 1 -1 
(schedule of events) and 1 -2 (blood volumes table).   Fixed typos 
in Section [IP_ADDRESS] & Section 10.4.[ADDRESS_15354] criteria,  modification of ex clusion 
criterion  #14, removal of unnecessary laboratory tests, and minor 
administrative changes  
6.4 15 February 
2018  South Korea specific amendment only.  Updated schedule of 
procedures & correction to blood volume in table  1-[ADDRESS_15355] criteria, modification of exclusion criterion #14, 
removal of unnecessary laboratory tests, and minor 
administrative changes. Updated study’s planned analysis.  
 
  
X4 Pharmaceuticals, Inc. 
Protocol X4P-001-RCCA, Version 7.0 (08  June 2018)   
98   
This protocol Version 7.0 has been prepared and approved by [CONTACT_1034].  
 
 
 
 
X4 Pharmaceuticals, Inc.  
 
UU______   
Signature [CONTACT_16070] 08, 2018

X4 Pharmaceuticals, Inc. 
Protocol X4P -001-RCCA, Version 7.0 (08 June 2018)  
99 18.2. Potential CYP -Related Drug -Drug  Interactions  
Strong CYP3A 
inhibitor1 Strong CYP3A 
inducer1Moderate 
CYP3A  
inhibitor2Moderate 
CYP3A  
inducer2CYP2D6 sensitive 
substrate1CYP2D6  
moderate 
sensitive 
substrate2
boceprevir, 
clarithromycin, 
cobicistat, 
conivaptan, 
danoprevir and 
ritonavir, 
diltiazem, 
elvitegravir and 
ritonavir, 
grapefruit juice, 
idelalisib, 
indinavir, 
itraconazole, 
ketoconazole, 
lopi[INVESTIGATOR_14484], 
mibefradil, 
nefazodone, 
nelfinavir, 
paritaprevir and 
ritonavir, 
ombitasvir and/or 
dasabuvir, 
posaconazole, 
saquinavir, 
telaprevir, 
telithromycin, 
tipranavir and 
ritonavir, 
troleandomycin, 
voriconazole  carbamazepi[INVESTIGATOR_050], 
enzalutamide, 
mitotane, 
phenytoin, 
rifampin,  
St. John’s wort  amprenavir, 
aprepi[INVESTIGATOR_053], 
atazanavir, 
cimetidine, 
ciprofloxacin, 
clotrimazole, 
crizotinib, 
cyclosporine, 
darunavir and 
ritonavir, 
dronedarone, 
erythromycin, 
fluconazole, 
fluvoxamine, 
fosamprenavir, 
imatinib, 
tofisopam, 
verapamil  bosentan, 
efavirenz, 
etravirine, 
modafinil, 
nafcillin  atomoxetine, 
desipramine, 
dextromethorphan, 
eliglustat, nebivolol, 
nortriptyline, 
perphenazine, 
pi[INVESTIGATOR_3924], 
thioridazine, 
tolterodine, 
venlafaxine  amitriptyline, 
encainide, 
imipramine, 
metoprolol, 
propafenone, 
propranolol, 
tramadol, 
trimipramine  
1 Prohibited.  
2 Use with Medical Monitor approval  only.  
Note: This list of drugs may not be a complete list, consultation  with the Medical Monitor is requested for any concerns about 
concomitant medication use.  
Sources: 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm080499.htm  